Entities

Bauer LeSavage is on Dimension’s current Research team. Stanford Bio-X independently identifies him as a Dimension research associate investing in platform biotechnology at the intersection of life science and technology. His Stanford2018 bioengineering fellowship researched scalable hydrogels for expanding human neural stem cells, advised by Sarah Heilshorn and neurosurgeon Theo Palmer. Dimension’s ownJune2026 post specifically credits his work on training data for biological AI models; research proposals are not clinical efficacy claims.

Simon Barnett is on Dimension’s current Research team. His prior primary2022 GEN speaker biography confirms genomics-analysis work at ARK, including DNA sequencing, molecular diagnostics, bioinformatics and synthetic biology. His primary ARK research2023 identifies his earlier life-sciences research leadership. Those historical employer titles are not asserted as current alongside Dimension.

Nikhil Namburi is published in Dimension’s current investment team directory. Dimension invests across computing and life sciences and publishes research on biological artificial intelligence, laboratory automation and frontier science. The directory verifies this professional affiliation but does not disclose a fuller individual biography, precise seniority, employment start day or personal cash investment.

Adam Goulburn is a Dimension co-founder and managing partner, identified in the firm’s March2026 SEC adviser filing as Adam Lander Goulburn. His primary BIO historical speaker biography documents life-sciences investing, neuroscience, brain-computer interfaces and stem-cell research, earlier Lux Capital work, a neuroscience postdoctoral fellowship at Weill Cornell and a PhD from the Australian Stem Cell Centre. Historical Lux transactions remain attributed to Lux, rather than being relabeled new Dimension investments.

Zavain Dar is a Dimension founder and managing partner, holding that position since March2022 according to Recursion’s current board biography. Previously a Lux Capital general partner from2014–2022, he invests across biotechnology and software. He engineered machine-learning and AI systems at Discovery Engine and studied symbolic systems and theoretical computer science at Stanford, where he researched in the AI lab. Recursion publishes his board membership sinceSeptember2016; no personal investment check is inferred.

Jefim Gewiet was a managing director of Apeiron Investment Group Ltd. named alongside Julien Höfer in Akili’s2022 original PIPE resale filing. Bionomics’2021 primary Schedule13D lists both as directors; Sensei Biotherapeutics’2024 filing additionally describes Gewiet as a financial advisor and a legal and judicial representative. These dated legal-management affiliations are historical and do not establish current parent employment or a personal Akili cash investment. A July2026 primary filing identifies Sanad Abushala as Apeiron’s sole statutory director. No authenticated original portrait was available in the retrieved current manager sources.

Julien Höfer is a lawyer and real estate and venture investor. His own current Van Houten & Co biography explicitly identifies him as a former managing director of Apeiron Investment Group. Akili’s2022 primary PIPE resale filing names him as a managing director of the legal Apeiron buyer, and earlier Bionomics regulatory filings corroborate his directorship. His own professional biography and issuer Periskop2024 announcement describe international-law-firm work in London, Frankfurt and Berlin and former chairmanship of atai Life Sciences. This is a historical Apeiron appointment; the2026 company filing instead names Sanad Abushala as sole statutory director. His original named own-company portrait is authenticated. No personal Akili check is inferred from beneficial-control wording.

Harrison Koontz’s public professional profile identifies employment at TRCM Fund and education at Virginia Tech. His specific current investment-team title and appointment date are not publicly verified; he is recorded as a source-qualified team member rather than an inferred partner or investment decision-maker.

Matthew Dicken is a serial entrepreneur and investor who founded Strategic Wealth Designers in 2002. His current employer biography identifies board service at Total Return Capital Management, alongside Healthbucks, Nexosome Oncology and Pneuma IP Holdings. He has worked in financial planning since age18, contributed to Kiplinger, written three books and appeared as a financial expert on major US television networks. His verified TRCM role is board service; a current executive title is not independently confirmed.

Sampson Chaim Glassman is identified as an indirect owner in TRCM IM LLC’s June2026 adviser filing through MT Larson Venture Partners LLC and TRCM MM LLC. Primary credit-vehicle offering disclosures separately name him as manager of TRCM Credit Fund segregated portfolios and identify TRCM Capital Advisors LLC as their investment manager. His legal ownership and credit-management roles are distinct from any personal cash investment in the venture portfolio.

TRCM Fund is the investment brand associated with South Miami’s TRCM fund-management platform, which combines private-equity approaches with investment in technology-driven businesses. Kamiwaza identifies TRCM Fund as an actual pre-seed investor in its enterprise AI orchestration business. The current investment manager TRCM IM LLC is an exempt reporting adviser, CRD341510/802136799, identified in its June2026 regulatory filing. Stephen Robert Green is its elected manager, while Sampson Chaim Glassman is an indirect owner through MT Larson Venture Partners LLC and TRCM MM LLC. Matthew Dicken’s own employer biography identifies him as a director of Total Return Capital Management. The adviser discloses eleven exact private fund/class vehicles, including US limited-partnership classes and segregated portfolios of TRCM Master Life Fund SPC in the Cayman Islands. TRCM Fund GP LLC is a separate general-partner entity, while the credit vehicles’ primary disclosures identify TRCM Capital Advisors LLC separately. Two US fund classes disclose completed subscriptions of $11,495,000 and $8,545,812, each with no remaining securities to be sold; these are individual class disclosures, not the adviser’s assets under management or an aggregate programme total. Master portfolios and feeder classes must not be summed as independent fundraising pools. The current fund website directs visitors to the TRCM Labs VIZN access platform; the separately named Labs operating company is distinguished from the investment manager and its legal funds.

Stephen Robert Green is the elected manager of TRCM IM LLC, the investment adviser identified in its June22,2026 primary regulatory filing, which reports his CRD2853952 identity. He is also named as manager of the TRCM fund-class issuers in their June2026 FormD disclosures. The legal manager, general partner and individual investment-fund classes remain distinct entities; these roles do not imply a personal investment in portfolio companies.

Perivoli Innovations is a Jersey-based purpose investment trust established in2016 and funded by the Perivoli Trust. It invests in early-stage medical and life-science university spinouts, climate technology, African digital businesses and productivity software, with investment gains supporting the separate Perivoli Foundation. It reports no third-party investors. Its trustees take investment decisions with advice from AMAS LLP principals James Alexandroff OBE and Barry McCorkell; these named advisory affiliations are distinguished from unnamed trustee appointments or employee titles. It is separate from the Perivoli Schools Trust and other charitable operating programmes. No external LP fund close or philanthropic budget is inferred from its investment mandate.

Barry McCorkell is named by Perivoli Innovations as an AMAS LLP principal providing advice to its trustees on investment decisions. Related Perivoli primary sources also identify him as a funding-trust trustee and Foundation trustee. These are separate legal entities; this profile records his actual published Innovations advisory affiliation rather than assuming an investment-trust trustee or employee appointment.

James Alexandroff OBE is an investor and philanthropist. Perivoli Innovations names him as an AMAS LLP principal advising its trustees. His own biography confirms this advisory work and describes co-founding Arisaig Partners in1996, gifting his ownership to the Perivoli Trust and establishing the Perivoli Foundation. Foundation and funding-trust affiliations are separate from the Innovations investment vehicle; no automatic private check or employee title is inferred.

Layer Global is a technology investment firm making concentrated investments in fast-growing companies across stages and regions. Its strategy centers on companies shaped by AI with recurring revenue, structural advantages and large markets. Founded by former General Atlantic co-president Anton Levy, it supports portfolio companies with hiring, customer expansion and strategic decisions as they scale, and seeks to increase its commitment to its strongest investments over time. The firm publishes offices in New York, San Francisco and Hong Kong.

Anton Levy founded Layer Global after serving as co-president of General Atlantic. He joined General Atlantic in1998 and invested through successive internet, mobile, social and cloud technology cycles. At Layer he focuses on concentrated partnerships with fast-growing technology companies in the AI era.

Arash Rebek leads capital formation and LP relations at Layer Global. His published speaker biography identifies earlier investor-relations roles at Khosla Ventures, Strategic Value Partners and Magnitude Capital, and an initial legal career at Skadden. He holds undergraduate and law degrees from the University of Chicago.

Cristyn Girolami is a Layer Global partner whose work centers on talent and organisational growth. Her published mentor biography describes more than25years supporting recruitment, leadership development, compensation and people strategy, including previous chief people officer positions.

Lauren Rakower is Layer Global’s chief compliance officer and general counsel, identified in its August2026 Form ADV. The filing records this executive affiliation beginning inJuly2026.

Zachary Kaplan is Layer Global’s co-founder and general partner, as identified in the manager’s August2026 Form ADV. His own launch post also describes his co-founder and partner role.

Raj Airey is a healthcare investor and company builder with international operating experience. Orthox identified him as Additio Investment Group’s investment representative in its February9,2022 financing announcement; the exact Additio job title and current status are not publicly specified. His current primary New Health IG biography describes earlier managing-director work at Pfizer and Baxter, company-building ventures including WizzCare and HealthStart, and experience in healthcare investment and business diligence. It also describes graduate study at London University, executive programs at Harvard Business School and INSEAD, and executive-coaching credentials. Historical corporate roles and prior investment performance are not assigned to Additio’s own funds, and a personal investment is not inferred from the institutional quote.

Economics-trained investment professional with prior audit experience and doctoral research at NTNU.

Venture investor focused on healthcare and selected semiconductor and deep-technology companies.

Director with experience in public administration, politics and private-sector governance.

Investor and technology executive with venture-capital and telecommunications experience.

Seed-fund investor with corporate finance, audit and management experience.

Software and deep-technology investor with prior banking and consulting experience.

Digital-business professional supporting Investinor’s systems and digitization.

Financial controller with business-administration training and prior operating-management experience.

Software and healthcare investor; previously co-founded and led venture activity at NTNU Technology Transfer.

Banking executive with finance, management and board experience.

Executive and asset-management professional with experience at Western Bulk, Umoe and Storebrand.

Technology entrepreneur and investor with experience developing, acquiring and selling software businesses.

Venture-fund investor with experience at Innovation Norway and DNB Asset Management.

Energy-technology investor with audit, transaction-support and advisory experience.

Financial-economics graduate with consulting experience in digitization, innovation and sustainability.

Financial-economics graduate with consulting, audit and financial-management experience.

Finance and accounting specialist with prior audit experience at PwC.

Lawyer experienced in business advice and disputes, with additional organization and management training.

Auditor and sustainability professional experienced in development finance, investigations and anti-corruption.

Finance graduate with quantitative and asset-management training; joined Investinor in 2026.

Communications professional specializing in public affairs, media relations, crisis communication and reputation.

Industrial-economics and technology-management graduate with investment-banking and technology-startup experience.

Data-science and economics graduate with finance training; joined Investinor in 2025.

Investor with experience in renewable-energy corporate venture capital and Innovation Norway.

Former Siemens executive with international strategic-management experience.

Long-serving investor and fund professional who became CFO in 2025.

Deep-technology and healthcare investor with growth-equity, investment-banking and audit experience.

Law-trained transaction professional with venture-fund, investment-banking and board experience.

Pre-seed investor responsible for Investinor’s Northern Norway co-investment mandate.

Aquaculture and technology investor; previously CFO at Norway Royal Salmon.

Technology executive experienced in scaling software businesses, acquisitions, listings and company sales.

Former Investinor CFO and acting CEO, serving as investment director since 2025.

Finance-trained investor with previous management-consulting experience at EY.

Organizational psychologist experienced in strategic and operational human resources.

Technology investor with financial-advisory and technology-M&A experience.

David Friedman, MD is managing director and senior analyst for the healthcare and biotechnology Averill strategy at Montanova Capital, formerly Suvretta Capital Management. He joined the manager in January2020 according to issuer filings. His previous experience includes healthcare analysis at Scopia Capital and biotechnology equity research at Morgan Stanley. He holds an MBA from Harvard Business School, an MD from the University of Pittsburgh School of Medicine and a biology degree from Duke University. His source-published board experience includes Click Therapeutics, Veradermics, Avalyn and Sapphiros; a company board role is not a personal cash ticket.

Andrew Jon Nathanson is general counsel and chief compliance officer of Montanova Capital, formerly Suvretta Capital Management. The current July2026 SEC filing identifies his officer role from March2014 and his legal/compliance responsibility. Issuer beneficial-ownership filings also show him signing for the manager and Averill funds; those signatures do not establish personal investment cash.

Glenn Michael Shepard is chief financial officer of Montanova Capital, formerly Suvretta Capital Management, according to the July2026 SEC FormADV. The filing records his officer status from September2011 and identifies him as a control person. That month-level appointment is not given a guessed day, and no unsupported prior career, education or portrait is assumed.

Kishen Mehta is chief investment officer of the Averill and Averill Madison healthcare strategies at Montanova Capital, formerly Suvretta Capital Management. His earlier roles include strategic advising for Biohaven, healthcare portfolio management at Surveyor Capital/Citadel, investment analysis at Adage Capital and Apothecary Capital, and life-science M&A at Evercore. He graduated in finance and accounting from NYU Stern in2007. His published work includes neuroscience and biotechnology investments; his separate VentureHaven founder affiliation supplies the authentic named portrait and is not treated as the same fund manager.

Aaron Cowen founded the investment manager historically called Suvretta Capital Management in2011, now branded Montanova Capital. He is chief executive officer in the July2026 SEC filing and chief investment officer of the generalist long/short Suvretta strategy on the current website. His earlier investment career includes Soros and serving as CIO for Steve Cohen, as described by the primary2026 Liquidity Summit. His authentic conference portrait is source-published; beneficial-control reporting is not a personal cash investment.

Montanova Capital LLC is the New York investment manager formerly named Suvretta Capital Management LLC. Formed in2011, the same SEC adviser with CRD165153 and file801-79962 reported its Montanova name change in the1July2026 FormADV; historical Suvretta transactions remain part of this manager’s history. Its current website identifies three strategies: Averill and Averill Madison, two healthcare-focused long/short equity strategies led by CIO Kishen Mehta, and Suvretta, a generalist long/short equity strategy led by CIO Aaron Cowen. Averill Master Fund Ltd and Averill Madison Master Fund Ltd are separately constituted Cayman legal master funds, with their own feeder entities; the manager is not itself a fund. Official filings also identify Suvretta Master Fund and its feeders. Regulatory assets under management, gross fund assets, securities holdings and offering targets are not reported here as newly raised cash or actual fund closes. The manager’s public relevance to neuroscience and deep technology includes Akili’s adaptive cognitive digital therapeutics and healthcare investment expertise, with David Friedman representing its Averill strategy on digital-therapeutic and biotechnology company boards. The2022 Akili PIPE participation is attributed at manager level with exact Averill fund/subscriber qualifications, separate from SPAC sponsor ownership, share exchanges or aggregate holdings. Current published leadership includes Aaron Cowen, Kishen Mehta, CFO Glenn Shepard and general counsel/chief compliance officer Andrew Nathanson; David Friedman is managing director and senior analyst for Averill, confirmed by current company biographies. Authentic portraits are available for Cowen, Mehta and Friedman from primary event/affiliated-company pages; no invented portraits or exhaustive private staff directory are asserted. The official current address is11East26thStreet,16thFloor,NewYork; older issuer filings at540MadisonAvenue are retained as historical.

Lourens D. Verweij is a co-founder and founding partner of Additio Investment Group, an international syndicate supporting healthcare and life-sciences entrepreneurs. Primary professional contributor material describes him as an investor, company builder and board advisor, and as chairman of LSHAccess Foundation. His contributed investment guidance emphasizes technology milestones, clinical evidence and how financing reduces development risk, rather than treating investigational products as already validated. The2022 venture.ch advisory-council booklet independently names his Additio founding-partner role. Wider current corporate appointments, education and any personal investment amounts require separate primary verification; institutional Additio checks are not assigned to him personally.

Additio Investment Group, branded AiG, is an international healthcare and life-sciences investment syndicate that combines capital from industry entrepreneurs, executives and investors with operating support and professional networks. Its own current website describes emphasis on European seed and Series A opportunities in medical technology, digital health and selected biotechnology or pharmaceutical businesses, sourced mainly through internal referrals. Its public portfolio links identify Gedea Biotech, SOM Biotech, VB Devices, Oxford Endovascular, Cytovation, Leixir, Orthox, neurocare group and Gasgon Medical. This supports relevance to neuroscience devices, technology-enabled mental-health care and biotechnology; portfolio products are not represented as clinically approved solely because the manager lists them. Oxford Endovascular independently named Additio as a participant in its April8,2021 Series A, and the manager reciprocally links the issuer domain, confirming identity independently of the similarly named US firm Addition. The own website also links a LinkedIn company slug spelled additoinvestmentgroup; that spelling is a brand alias rather than a different investment entity. AiG1 is a pledge-fund structure launched in2019 and described as allocated to portfolio companies; its commitment total, individual tickets and exact closing dates are undisclosed. It is not presented as an independently verified regulated legal partnership or a conventional committed fund. Primary industry-event material identifies Spain participation and co-founder/founding partner Lourens D. Verweij, but the website does not publish a complete team roster, precise operating-company legal suffix, legal fund vehicle, or principal office address. Those fields remain unclaimed rather than inferred from namesakes or commercial databases.

Cytotrait is a Manchester biotechnology spinout developing crop traits through editing of chloroplast and mitochondrial genomes. Its proprietary Mutant Organelle Selection System (MOSS) uses programmable nucleases and selection against unmodified gene copies to spread introduced genes or edits throughout organelles, rapidly producing homoplasmy, where all copies carry the intended genetic change. The approach aims to enable stable, high-level trait expression with simpler trait stacking, backcrossing and containment. Cytotrait is developing applications in wheat, maize, potato and canola for yield, resilience, pest and disease resistance, hybrid-seed production and new food or industrial traits. These are development programmes and potential applications rather than claims that every resulting crop product is already commercialised.

IVFmicro develops an oil-free microfluidic embryo-culture system for assisted reproduction. Its device uses controlled small volumes of nutrient-rich fluid to provide a stable environment around developing embryos, reduce repeated handling and minimise variation between laboratory operators. Designed to fit existing incubators and IVF workflows, the platform combines microfluidic engineering with reproductive biology and is being developed for human IVF and veterinary reproduction. The company is based at Nexus in Leeds and is conducting preclinical development, verification and validation; its published regulatory pathway concerns future FDA and CE clearance rather than confirmed approvals.

Anil Day co-founded Cytotrait and advises its science. A University of Manchester reader, he researches chloroplast biology and genetic engineering for crop improvement and co-invented the MOSS platform with Junwei Ji.

Cassie Doherty is a Northern Gritstone investment director with experience in life sciences company building, diligence, strategy, transactions and governance. IVFmicro publishes her in its board section, and Companies House lists her as Cassandra Clare Doherty.

Enrico Sangiorgio is executive chair of IVFmicro. His experience spans healthcare executive leadership, business development and scaling early-stage ventures, including leading Sensiia as CEO and securing Series C investment.

Helen Parris is IVFmicro’s chief executive officer. She holds a PhD in reproductive medicine and has led commercial strategy, market access and product launches in regulated life sciences markets, including senior positions at Arecor Therapeutics, Albireo Pharma and Gilead Sciences.

Helen Picton co-founded IVFmicro and is its chief scientific officer. A University of Leeds professor, she specialises in female reproductive biology, embryology, fertility preservation and assisted reproduction. She founded the university’s Reproduction and Early Development research group and is scientific director of Leeds Fertility.

Ian Jepson joined Cytotrait as a non-executive director in September 2026. He spent 35 years at Syngenta and predecessor businesses, with leadership roles in seeds research, genome editing, trait discovery and crop breeding. He holds a University of Birmingham PhD in genetics.

Junwei Ji co-founded Cytotrait and is its executive director. His University of Manchester PhD research on precise chloroplast DNA mutagenesis contributed to the MOSS platform. He led the company’s ICURe commercialisation programme and previously worked in hybrid maize breeding.

Tim Brears is executive chair of Cytotrait. He has led biotechnology companies including Evonetix, Xention and Gendaq and worked in business development at Ciba-Geigy/Novartis. He holds a Cambridge PhD in plant molecular biology and a Duke MBA.

Virginia Pensabene co-founded IVFmicro and is its chief technology officer. A University of Leeds associate professor, she researches microfluidics, biomedical engineering and organ-on-chip technologies. She holds a PhD in Humanoid Technologies from the University of Genoa and the Italian Institute of Technology, and previously founded medical startup WinMedical.

Mario Frendo formerly served as a statutory director of Apeiron Investment Group Ltd., signing primary2025 and May2026 public regulatory filings. His own2026 professional announcement states that his Apeiron tenure ended and that he moved to Deriv as Senior Legal Counsel. The exact departure day is unpublished in retrieved sources, so structured dates remain unknown; the role is historical. No current Apeiron employment or personal company investment is inferred. No authenticated original portrait was available in the retrieved primary profile sources.

Sanad Abushala is Apeiron Investment Group Ltd.’s sole statutory director and Head of Treasury, explicitly identified in its July17,2026 primary Schedule13D filing. His principal professional address is in Birkirkara, Malta, and the filing identifies Croatian citizenship. These are source-confirmed legal and treasury positions; no education, earlier employers, founding role or personal investment is inferred. No authenticated original portrait was available in the current own manager sources retrieved.

Apeiron Investment Group is Christian Angermayer’s discretionary investment firm, legally Apeiron Investment Group Ltd., a Maltese private limited company. Its current website describes a global investment approach using both its proprietary balance sheet and external capital: direct private and listed company investments, anchor commitments to emerging asset managers and stakes in their general partners. Its published focus includes biotechnology, deep technology, fintech and crypto, experiences and sports, real estate and natural resources. Neuroscience relevance includes cognitive digital therapeutics and the development of psychedelic treatments for mental health. Its approximately USD7 billion of managed internal and external capital is AUM, not a closed fund. Current primary legal filings identify Sanad Abushala as its sole statutory director and Head of Treasury; Angermayer is its founder and controlling shareholder. Former director Mario Frendo’s departure is independently confirmed by his own announcement and is not presented as a current appointment. The current own website publishes no complete staff directory; a developer-hosted replica of the former team page is excluded as unverified evidence. Presight Capital and re.Mind are separately identified affiliated investment managers, with their own legal funds and existing canonical records retained. Presight Capital Management I, LLC is the GP of Apeiron Presight Capital Fund II, LP, and Apeiron and Fabian Hansen are its managing members. This affiliation does not move all Presight or re.Mind investments or fund assets to the parent. Akili’s completed2022PIPE confirms an original direct Apeiron USD1 million subscription, separate from legacy holdings. This exact Maltese group and apeiron-investments.com domain are distinct from Apeiron Capital’s real-asset manager, Greek Apeiron Ventures/apeiron.vc, Italian Apeiron Management and Apeiron Ventures’ other namesakes.

Dazi Delian Investment Management is a private equity and venture-capital fund manager within the Delian Capital group. It manages technology and healthcare investment vehicles, including a specialist Shanghai neuroscience fund that backs tools for brain research, neurological and psychiatric disease treatments, and other brain-science technologies. The wider group invests in technology-driven early and growth-stage companies across semiconductors, intelligent equipment, AI and innovative medicines.

Shane Wilson invests at Citta Capital in early-stage B2B AI, deep technology and robotics. His 2026 podcast interview identifies him as Managing Partner, while Citta’s own public event announcements describe him as Venture Partner. His background includes startup go-to-market, workforce technology, commercialization, enterprise strategy and venture investing. He helps founders connect technical products with customer value, pricing and defensible businesses.

Fred Sun is a member of Citta Capital’s publicly identified investment team. Current firm communications tag his own Fred S. profile alongside Jim Mao and Shane Wilson in discussions of agentic AI, enterprise adoption, defensibility and portfolio companies. His current exact operating title is not published in those primary communications; older investment-directory titles are not treated as a confirmed current promotion.

Jim Mao is Founding and Managing Partner of Citta Capital and Managing Member of Citta Capital Management, LLC. He founded the venture firm in 2020 to back early-growth technology companies across AI, enterprise software, cloud and healthcare technology. He previously was a Partner at WestSummit Capital, where he led investing in enterprise, cloud, big data, AI, robotics and digital media, following executive roles in startup and established technology businesses. His current regulatory filing confirms his Managing Member role; his earlier director biographies describe five co-authored US patents and education at the University of Southern California.

Citta Capital is a Palo Alto venture-capital firm founded in 2020, focused on early-stage and early-growth technology companies. It invests in artificial intelligence and machine learning, cloud and data infrastructure, enterprise software, healthcare technology, robotics and other emerging technologies. Founding and Managing Partner Jim Mao is the Managing Member of legal adviser Citta Capital Management, LLC, CRD322343, which files as an exempt reporting adviser. Its current public communications identify Jim Mao, Fred Sun and Shane Wilson; Shane is described as Venture Partner in firm posts and Managing Partner in his 2026 interview. The firm helps entrepreneurs develop products, enter markets and scale globally, drawing on startup and operating experience. Its neuroscience and life-science portfolio includes voice-based mental-health technology Kintsugi, stroke-monitoring developer Zeit Medical, bioelectronic-medicine company SetPoint Medical, Ordaos Bio and Synaptec Health. Its AI and deep-tech portfolio also includes Kamiwaza, Avoca, Visto and Finwave. Three exact legal private vehicles are disclosed in its March2026 adviser filing: Citta Capital, LP; Citta Capital Emerging Tech LLC; and Citta Capital Growth Opportunity LLC. Verified completed fund commitments and closing dates are undisclosed; reported asset values do not establish fundraising closes. Citta’s 2020 venture manager is distinct from the older Asian-equities firm of the same name and the Singapore entity with an unverified relationship.

Pacertool develops the PaCRTool system to help clinicians select heart-failure patients for cardiac resynchronization therapy and optimize pacing-lead placement during pacemaker implantation. Its technology uses a cardiac electromechanical biomarker to quantify whether pacing improves synchronization, supporting an individualized approach to treatment. The Norwegian medical-device company has pursued early feasibility studies and a US regulatory-development strategy. Current product availability or regulatory clearance has not been independently established; the issuer’s published product description concerns development rather than an approved clinical product.

Pluvia Biotech is a University of Bergen spin-out developing medicines for rare genetic disorders caused by misfolded proteins. Its lead candidate, PBAS499, is an oral pharmacological chaperone designed to stabilize the phenylalanine hydroxylase enzyme and restore its activity in phenylketonuria (PKU), a metabolic disorder in which excess phenylalanine can damage the brain. The company is completing preclinical work and preparing for clinical development, while seeking to apply its protein-stabilization platform to other rare diseases. Pluvia AS is its Norwegian legal company.

Molecular biologist working on mouse-colony maintenance, genotyping and in-vivo experiments.

Pharmacist and cell-biology researcher overseeing cell culture and preclinical development.

University of Bergen biochemistry professor researching protein structure, stability and pharmacological chaperones.

Healthcare investor with international asset-management and equity-analysis experience at NBIM and UBS.

Cardiology professor researching devices and heart failure, named in the issuer’s 2022 scientific advisory board.

Cardiologist researching device therapy for arrhythmias and heart failure, named in the issuer’s 2022 advisory board.

Rare-disease biotechnology executive with clinical, regulatory and company-building experience; appointed CEO August 24, 2026.

Cardiologist and founder of Pacertool, independently identified by Oslo University Hospital and Simula. Executive title is from the dated issuer release, not independently confirmed as current.

Medical-device executive named CEO in Pacertool’s October 2022 release. Augere Medical now publishes him as its CEO; no exact Pacertool departure date is established.

Biomedicine researcher planning and conducting in-vivo experiments and transgenic mouse studies.

Cardiology professor and clinical-trial investigator, published in the issuer’s 2022 scientific advisory board announcement.

Named in Pacertool’s public company LinkedIn employee list. Precise current executive title is not independently confirmed.

Cardiac electrophysiologist specializing in ablations and cardiac-device implantation, named in the issuer’s 2022 advisory board.

Biomedicine researcher supporting protein purification, compound screening and blood-sample processing.

Nanoscience-trained researcher conducting phenylalanine analysis, enzyme-activity assays and in-vitro experiments.

Pluvia announced his transition from CEO to board member on August 24, 2026.

Ms. Lawrence has served as trustee of the Delaware Funds by Macquarie, as a director of its New York and Australian Stock Exchange-Listed close-end funds, DEW/VCF/DDF/VMM/VFL/IVH, and on its Audit and Investments Committees since 2021. She has served as a trustee of its legacy Ivy and Waddell and Reed Mutual Funds Complex Trust, and on its Governance Committee, since 2019. Ms. Lawrence was the Executive Vice President and Chief Financial Officer of Children’s Mercy Hospital, a comprehensive pediatric medical center in Kansas City, Missouri, from 2005 to 2016 and the Executive Vice President and Chief Administrative Officer of Children’s Mercy Hospital from 2016 to February 2019. She was Senior Vice President and Treasurer of Midwest Research Institute, an independent, non-profit, contract research organization, located in Kansas City, Missouri, and subsequently its Chief Financial Officer. Ms. Lawrence spent twenty-six years in professional or management positions in the architecture, real estate, investment banking, financial services, packaging, and medical research industries. Ms. Lawrence also serves as a member of the board of directors of Evergy, Inc., a publicly traded company that provides clean, safe and reliable energy to 1.6 million customers in Kansas and Missouri, where she serves as chair of the Nominating, Governance, and Corporate Responsibility Committee, and as a member of the Compensation and Leadership Development Committee. Ms. Lawrence serves on the board of directors of American Shared Hospital Services, a publicly traded company that provides radiosurgical and radiation therapy equipment and services, based in San Francisco, California, where she serves as chair of the Audit Committee and as a member of the Nominating and Corporate Governance Committee. Additionally, she serves on the board, as chair of the Risk Oversight Committee, and on the Governance, Compliance, and Talent and Compensation Committees, of Recology, a large, private, Employee Stock Ownership Plan company that provides collection and disposal of municipal solid waste, recycling, and organic/compost to commercial and residential customers in California, Oregon, and Washington. Ms. Lawrence has been the chair of the board of directors of the Heartland Chapter of the National Association of Corporate Directors (NACD), was named one of its Directorship 100, and an NACD board leadership fellow. She serves on the boards of directors of various charitable, non-profit and civic organizations, including the Hall Family Foundation, the Nelson-Atkins Museum of Art, and Women Corporate Directors. Ms. Lawrence is a graduate of Vassar College, where she received her Bachelor of Arts in psychology. She also received a Master of Architecture from the Massachusetts Institute of Technology and a Master in Business Administration from Harvard Business School. We believe Ms. Lawrence is qualified to serve as a member of our Board because of her work experience, financial background, academic background and service on corporate and charitable boards.

Mark Capone has served as a member of our Board of Directors since July 2026 and is a seasoned healthcare executive with more than 40 years of leadership experience across the diagnostics and life sciences sectors. Previously, he served as Chief Executive Officer of Myriad Genetics, where he led the company’s transformation into a focused precision medicine organization, expanding its molecular diagnostics portfolio and strengthening its commercial execution. Prior to serving as CEO, he held several senior leadership roles at Myriad during his 17-year tenure, including President and Chief Operating Officer. Earlier in his career, Mr. Capone held leadership positions at Eli Lilly and other healthcare organizations, building deep expertise in pharmaceutical commercialization, strategic planning, and business development. He currently serves as a non-executive director at Mesa Laboratories, where he is Chair of the Compensation Committee, and at Owlstone Medical, where he serves on the Compensation Committee. Mr. Capone received a Master of Science in Chemical Engineering and a Master of Science in Management from the Massachusetts Institute of Technology, and a Bachelor of Science in Chemical Engineering from Pennsylvania State University. We believe that Mr. Capone’s qualifications to serve on our Board of Directors include his extensive experience commercializing complex diagnostic products, his deep understanding of reimbursement and payer environments, and his proven ability to scale innovative diagnostic platforms and build high-performing commercial organizations.

Mansoor Raza Mirza, M.D. has served as a member of our Board since December 2014. Dr. Mirza is Chief Oncologist at the Department of Oncology, Rigshopitalet — the Copenhagen University Hospital, Denmark and Medical Director of the Nordic Society of Gynaecological Oncology, or NSGO. Dr. Mirza is Chairman of the European Network of Gynaecological Oncological Trial groups, or ENGOT. Dr. Mirza is both a medical and radiation oncologist, with a primary focus in non-surgical treatment of gynecologic cancers. His key academic goals are to promote clinical research, international trial collaboration and education, and he has broad experience in clinical protocol development, trial conduct and clinical trial regulations. Dr. Mirza is the author of several phase 1, 2 and 3 studies. Several of those studies led to FDA and European Medicines Agency registrations. He serves on several Independent Data Safety Monitoring Committees of international studies. He is an invited speaker at several international conferences, such as “Meet the Professor” at American Society of Clinical Oncology and “Presidential Symposium” at European Society for Medical Oncology. He is the author of global consensus guidelines for the management of ovarian cancer and of European guidelines for the management of several gynecological malignancies. His other current appointments include service as ESGO Council Member (European Society of Gynaecological Oncology), Executive Director of GCIG (Gynecologic Cancer InterGroup), Vice-Chairman of the Danish Gynecological Cancer Society, faculty member of the European Society of Medical Oncology and of ESGO. He also serves on the board of directors of Karyopharm Therapeutics Inc., a public pharmaceutical company and has served as a clinical consultant to Karyopharm Therapeutics Inc. since 2010. He has multiple publications in high-impact journals, including several publications in the New England Journal of Medicine and the Lancet. He holds an M.D., Diploma in Surgery and Diploma in Clinical Oncology from the Pirogov Moscow State Medical Institute as well as post-graduate education and certification in radiation and medical oncology from the University of Southern Denmark. We believe Dr. Mirza’s qualifications to serve on our board include his expertise in gynecologic cancers, and his knowledge of our company and its business through service on our board since December 2014.

Jacky Cheung is Head of Finance of CLSA Capital Partners in current own public management pages. He provides financial and governance oversight of the affiliate’s strategies and previously worked in finance at CITIC Capital. He is recorded with his exact finance identity, distinct from the singer and other namesakes.

Derek Hung leads transaction management at the affiliated CITIC Securities CLSA Capital Partners business, which he joined in2021. Its own biography describes his legal and investment experience at China-ASEAN Fund, CCB International and Clifford Chance and qualifications in England and Wales, New South Wales and Hong Kong.

Kim Kamdar, Ph.D. has served as a member of our Board since November 2011, and as Board Chair since May 2023. Dr. Kamdar is currently a Partner at Domain Associates, LLC, a venture capital firm, where she has worked since 2005. Prior to Domain, Dr. Kamdar was a Kauffman Fellow with MPM Capital, as well as a research director at Novartis International AG. Dr. Kamdar is currently Chair of the Board of Directors of Seraphina Therapeutics and Truvian Sciences, Inc. and serves on the board of directors of EvoFem Biosciences, Inc. (Nasdaq: EVFM), Obalon Therapeutics, Inc. (Nasdaq: OBLN) and Singular Genomics Systems (Nasdaq: OMIC). Dr. Kamdar currently serves on the board of several private companies including: Epic Sciences, Inc., Alume Biosciences and Pleno, Inc. Dr.Kamdar serves as an advisory board member of Dr. Eric Topol’s NIH supported Clinical and Translational ScienceAward for Scripps Medicine and is also on the nonprofit board for Access Youth Academy, an organization that is transforming the lives of underserved youth through academic enrichment, health and wellness, social responsibility and leadership through squash. Dr. Kamdar received her B.A. from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University. We believe Dr. Kamdar is qualified to serve on our Board of Directors based on her extensive experience working and serving on the boards of directors of life sciences companies and her experience working in the venture capital industry and her knowledge of our company and its business through service on our board since November 2011.

Amy Jia is Director of Credit Business in CLSA’s public alternative-investment management page. The affiliate’s own biography additionally identifies her as Head of Healthcare Investment Division, CLSA China Growth Fund, following Goldstone healthcare experience. This unit-specific role is not a direct claim that the broad CLSA platform subscribed to each affiliate fund.

Joshua Phillips has served as a member of our Board since January 2011. Since 2008, Mr. Phillips has been a Managing Partner of Catalyst Health Ventures (CHV), a venture capital fund investing in medical technology and life science companies.Mr. Phillips led Catalyst’s investments in Novazyme Pharmaceuticals, Inc. (acquired by Genzyme Corp.), BioTrove, Inc. (acquired by Life Technologies Corp.), Biocius Life Sciences, Inc. (acquired by Agilent Technologies, Inc.), Vortex Medical, Inc. (acquired by AngioDynamics), Allegro Diagnostics, Inc. (acquired by Veracyte, Inc.), SevenOaksBiosciences (acquired by Medline Industries, Inc.), Pavilion Medical Innovations and Cruzar Medsystems, in addition to our company. Prior to joining Catalyst, Mr. Phillips was the Managing Partner of Catalyst Health and Technology Partners prior to CHV, where he led investments in Novazyme Pharmaceuticals, Inc. (NASDAQ:SNY), BioTrove, Inc. (NYSE:TMO) and Biocius Life Sciences, Inc. (NYSE:A). Mr. Phillips is a director at several privately held companies, including Conformal Medical, Inc., Brixton Biosciences, Inc., Saphena Medical, Inc., and Cruzar Medsystems, Inc. Mr. Phillips holds an M.B.A. from the Harvard Business School and a B.E. in Electrical Engineering and Mathematics from Vanderbilt University. We believe that Mr. Phillips’ qualifications to serve on our board include his extensive experience in the life science, diagnostics and medical device markets, his extensive experience serving on boards as Chairman, Lead Director, Audit & Compensation Committee Chair and Member and his knowledge of our company and its business through service on our board since January 2011.

Deborah Feng is an alternative-investment division leader. The CLSA platform page calls her Head of Strategy and Business Development and Executive Director, Private Equity; the affiliate’s own biography calls her Deputy Head of CITICS CLSA Capital Partners. Both published titles are retained rather than inferring an appointment date. Her previous work includes Goldstone healthcare investment and Zhong De Securities.

Baifeng Hu is a CITIC CLSA Management Committee member and leads its separately named alternative-investment business, CITIC Securities CLSA Capital Partners. His own biography describes prior Goldstone and CDB Capital experience and investments in healthcare, technology and advanced manufacturing. His affiliate leadership is qualified within the broader CLSA platform.

Dr. Barlow has served as Chief Executive Officer of Jane Barlow & Associates, LLC, a consulting firm focused on value-based health care services, since January 2017, and Executive Vice President and Chief Clinical Officer at Real Endpoints, a data, analytics, and advisory firm, since January 2017. She currently serves on the board of directors of ContraFect Corp., a publicly traded biotechnology company, and Viracta Therapeutics, Inc., a publicly traded precision oncology company. Dr. Barlow also serves on the board of directors of Point Health, a healthcare navigation platform, the advisory board of Refactor Health, and the Biotech Advisory Board of Pictet Asset Management, an asset management firm. Prior to her current roles, Dr. Barlow was Associate Chief Medical Officer at CVS Health and Chief Medical Officer of CVS Health’s Government Services arm where she successfully implemented industry-leading clinical strategies supporting drug purchasing, distribution, and utilization management. Formerly, she served as Vice President of Clinical Innovation at Medco Health Solutions, leading the adoption of cutting-edge therapeutic programs through all aspects of pharmacy. Dr. Barlow previously served on the board of directors of Momenta Pharmaceuticals, Inc., (prior to and during its sale to Johnson and Johnson), Therapeutics MD Inc., and SilverScript Insurance Company. Dr. Barlow received her medical degree from Creighton University School of Medicine and subsequently completed her residency in occupational and environmental medicine at The Johns Hopkins University, where she also earned her M.P.H. Additionally, she holds an M.B.A. from the University of Alabama. She is board-certified in occupational medicine and a fellow of the American College of Occupational and Environmental Medicine and the American College of Preventive Medicine. She is a diplomat of the American College of Physician Executives and a member of the American Medical Association.

Edward Park leads CLSA institutional equities and is Deputy CEO of CITIC Securities International in its September2025 own release. He joined CLSA in1998 and has held sales, trading and execution leadership across Asian offices. His authentic portrait comes from the Shanghai Stock Exchange’s named2022 conference programme, with his current title independently sourced from the firm.

Ruan van Vuuren is a Cayman Islands board member and fund director at International Management Services. The company biography identifies chartered-accountancy, alternative-investment and governance qualifications, earlier Cayman Islands Monetary Authority work and PwC audit experience. Alyeska’s March 2026 Form ADV names him in governance of its master and two feeder vehicles. This is an external governance affiliation, distinct from the same-name supply-chain consultant and from employment or personal investing at the manager.

Ebony Myles-Berry is a Cayman Islands fund director at International Management Services. Her own biography describes earlier Maples Fiduciary Services and regulatory/administrative work and qualifications in finance and investment-fund governance. Alyeska’s March 2026 Form ADV names her on the governance lists of its master and two feeder vehicles. She is recorded as an external fund director, without inferring employment at Alyeska or personal portfolio allocations.

Yang Yu, also rendered Yu Yang, is the head of investment banking at CITIC Securities International and a director of CLSA Limited and other named subsidiaries in own statutory filings. His role is qualified by legal unit and is not an assumed private-equity portfolio attribution.

Gregory C. Critchfield, M.D., M.S. served as our Chairman, President and Chief Executive Officer from November 2011 through May 2023. Dr. Critchfield brings decades of experience in the diagnostics industry, including a proven track record of successfully launching diagnostics products and significantly growing revenues for leading diagnostics companies. Previously, Dr. Critchfield was President of Myriad Genetic Laboratories, a wholly-owned subsidiary of Myriad Genetics, Inc., a molecular diagnostics company, from 1998-2010. Under his leadership, Myriad launched seven novel molecular diagnostic products across a variety of technology platforms and increased annual revenues from $2.2 million to $326.5 million. Prior to Dr. Critchfield’s role at Myriad, he served as Senior Vice President, Chief Medical and Science Officer of Quest Diagnostics (formerly Corning Clinical Laboratories). Prior to Quest Diagnostics, Dr. Critchfield was the Director of Clinical Pathology at Intermountain Health Care. Dr. Critchfield has served on the boards of Saladax Biomedical Inc., BioTrove Inc., Biocius Life Sciences, Inc., Integrated Diagnostics, Inc., Nodality, Inc., Metamark Genetics, Inc., Lantos Technologies and Condor Therapeutics, Inc., and currently serves as a director of Epic Sciences. He also served as both a reviewer and an NIH Study Section Chair for biomedical computing grants over a period of time encompassing fifteen years. He holds a B.S. in Microbiology from Brigham Young University, an M.S. in Biophysical Sciences from the University of Minnesota and an M.D. from the University of Utah College of Medicine. We believe that Dr. Critchfield’s perspective and experience as our President and Chief Executive Officer, as well as his depth of experience in the diagnostics industry, provide him with the qualifications and skills to serve on our board of directors.

Christopher (Chris) Bowring is a Cayman Islands professional director at International Management Services, whose own biography identifies accounting, governance and trust qualifications and prior fiduciary leadership. Alyeska’s March 2026 Form ADV explicitly names him in the governance of Alyeska Master Fund, Aleutian Fund and Alyeska Fund. This external fund-board affiliation does not make him an Alyeska portfolio manager, employee or company investor.

Jianqiang Xu, also known as James Xu, is Co-Chief Executive Officer of CITIC CLSA from February2025 according to own2025/2026 disclosures. He oversees multiple business lines including equity derivatives, wealth and asset management after joining CITIC Securities in2005. His corporate platform responsibilities are distinct from the separate managers’ fund corpus.

Benliang Shi, also rendered Shi Benliang, is a director of CITIC Securities International and CLSA subsidiaries in own statutory disclosures. He joined CITIC Securities in2000 and has held finance and wealth-management leadership. This statutory group role does not imply a personally attributed CLSA venture check.

Jennifer Zibuda has over 15 years of experience in investor relations, corporate communications, and capital markets across the biotechnology and healthcare sectors. As Head of Investor Relations for Sera, she leads investor engagement, oversees quarterly earnings communications, and partners with executive leadership to support the company’s strategic and financial messaging. Jennifer works closely with finance and legal teams to ensure consistent and compliant disclosures, and collaborates cross-functionally on communications related to partnerships, business development, and corporate growth initiatives. Prior to joining Sera, Jennifer served as Senior Director of Investor Relations at Vaxcyte where she helped evolve the the company’s shareholder base as it advanced into late-stage clinical development. She previously held investor relations and corporate communications roles at Prothena Biosciences, Portola Pharmaceuticals, and Alkermes. Jennifer holds a Master of Arts in Corporate Communication and Public Relations from Sacred Heart University and a Bachelor of Arts in Psychology from the University of Connecticut.

Brent Metrick Cunningham is Alyeska Investment Group’s chief compliance officer. The March 23, 2026 Form ADV names him with the title acquired in February 2018 at month precision; the manager’s August 4, 2026 SEC N-PX filing independently confirms his current role. His public professional profile identifies Alyeska and California Western School of Law. Portfolio reporting and regulatory signatures are not evidence of personal equity checks.

Adrienne Lugo has over 20 years of leadership experience in women’s health and molecular diagnostics, with a strong track record of building high-performing teams, expanding market access, and partnering with physicians and health systems to deliver innovative testing solutions. Adrienne has served in commercial leadership roles at BillionToOne and Bayer Healthcare, where she was instrumental in driving growth and advancing adoption of novel diagnostic technologies. As Head of Sales and Strategic Accounts, Adrienne leads the company’s commercial strategy and key partnerships to support continued growth and broader adoption of Sera’s technology. Her deep expertise and strategic approach will be critical as the company expands its impact on maternal and fetal health. Adrienne began her career in healthcare sales and has held roles of increasing responsibility across the diagnostics and life sciences sectors, consistently delivering strong results in competitive and evolving markets. Adrienne is the proud mother of three children (triplets) and resides in Tampa with her family and rescue dog. She is driven by a strong sense of purpose, which aligns closely with Sera’s mission to improve pregnancy outcomes for mothers and babies.

Chunbo Li, also rendered Li Chunbo, leads CITIC CLSA and its parent CITIC Securities International. Own group publications identify him as chairman and CEO and a director of CLSA Limited and CLSA B.V. His group governance capacity is distinguished from personally executing the platform’s historical investments.

CLSA, currently branded CITIC CLSA, is a Hong Kong capital-markets and investment platform established in 1986. It operates across Asia, Australia, Europe and the Americas, providing institutional equities, corporate finance, capital markets, research, asset management and related services. The platform is part of CITIC Securities International, which acquired CLSA in 2013 and integrated the businesses under the CLSA brand in 2017. CLSA Limited and its holding company CLSA B.V. are distinct from the parent and from separately named affiliated managers. Akili’s August 9, 2018 issuer announcement explicitly names CLSA as an investor in its USD 13M Series C extension; the historical subscribing CLSA legal vehicle and individual check are unpublished. CLSA is not assigned an inferred 2021 Akili Series D investment. Current group and investment-division leadership are recorded with unit-specific qualifications. CITIC Securities CLSA Capital Partners is the separate alternative-investment business, while CITIC Securities Asset Management (HK), formerly CLSA Asset Management, manages public-market products. Their fund strategies, approximately USD 5B alternative assets under management, parent bond programmes and advisory mandates are not recorded as CLSA fund closes or allocated to its historical Akili check. A complete current firmwide employee directory and most individually verified portraits are not publicly published on the reviewed management pages. Its own October11,2018 announcement identifies AlphaLabs as a new fintech investment business focused on AI, automation, data and related technologies, and confirms investments in Epistema inOctober2018 and Symphony Communication Services inApril2018. These are qualified platform investments; exact legal subscriber vehicles and company profiles require separate audits.

Jason Aaron Bragg is Alyeska Investment Group’s chief financial officer, named in its March 2026 Form ADV and May 2026 SEC signatures. The ADV records the CFO role from February 2008, at month precision, and a trustee role in Alyeska Partners Trust from March 2024. He is also a named director/governance participant for the manager’s master and feeder vehicles. His fund or trust roles are distinguished from a personal portfolio check; no exact appointment day is inferred.

Liana Burns has nearly 15 years of experience in payer, health system, and non-profit environments where she focused on building and deploying population health strategies. As Head of Payer, Government & Strategic Partnerships she is responsible for leading Sera’s strategic partner engagement strategy to drive adoption and coverage. She partners with stakeholders to align frameworks that improve maternal health outcomes with a strong emphasis on value-based adoption, health equity, and population health impact. Before joining Sera, Liana was deeply engaged in Elevance Health’s whole health strategy during its inception and operationalization in Medicaid. She furthered the company’s maternal health strategy, specifically expanding access to doula care across the country. Additionally, she designed social care and health equity strategies across a nationwide footprint, integrating a community-based approach to the business. Liana began her career in patient advocacy, working both at non-profits and community hospitals in the DC, Maryland, and Virginia area building population health interventions, patient engagement strategies, and participating in advocacy coalitions. Liana holds a Master of Health Administration from the Johns Hopkins Bloomberg School of Public Health and a Bachelor of Science in Public Health from George Washington University. She lives in Brooklyn, NY and spends her free time training for races and hiking with her blue heeler, Remy.

Anand Christopher Parekh founded Alyeska Investment Group in 2008 and is its chief executive officer, verified by the March 2026 SEC Form ADV and current transaction filings. The University of Michigan identifies degrees in English and mathematics and earlier work at Deutsche Bank and Citadel, where he headed equities. The ADV names him in governance of Alyeska Master Fund and its feeder vehicles. Deemed beneficial ownership through management authority does not establish a personal company investment. He is distinct from the same-name physician/public-health leader at the Bipartisan Policy Center.

Cassondra joins Sera with more than 15 years of experience in healthcare, diagnostics, and commercial leadership, bringing a proven track record of driving growth, adoption, and innovation across women’s health and molecular diagnostics. Most recently, she served as Director of Marketing for Molecular Diagnostics at Waters Corporation via acquisition from Becton, Dickinson and Company, where she led commercialization strategies for women’s health and infectious disease portfolios. Throughout her career, Cassondra has successfully launched 14 products and most recently led clinician and consumer activation efforts to expand access to cervical cancer screening through innovative care models, including at home testing solutions. She is known for translating complex clinical science into compelling customer value propositions that drive provider adoption, behavior change, and business growth. Her expertise spans commercialization, market development, key opinion leader engagement, omnichannel marketing, and cross functional leadership. Outside of work, Cassondra enjoys competing in bowling tournaments, cooking with friends and family, and exploring new restaurants and culinary experiences. She believes many of life’s greatest connections are built around shared experiences, whether in the workplace, on the lanes, or around the dinner table. Cassondra is excited to bring her passion for women’s health, commercialization, and team development to Sera as the company continues its mission to improve outcomes for mothers and babies.

Nikki Martin has over 25 years of experience with hands-on successes in building and leading top-performing teams, overcoming technical challenges, and achieving desired outcomes in the laboratory, CRO, IVD, medical device, and biopharmaceutical manufacturing sectors in US and international settings. Nikki has served as our Vice President of Quality/Regulatory and Privacy Officer since May 2020. In her role as Vice President of Quality/Regulatory and Privacy Officer, she oversees all quality assurance and regulatory activities within Sera, including the CAP/CLIA laboratory and regulated activities throughout the company. She works very closely with the heads of all departments to ensure the highest quality results delivery and compliance with applicable regulations. Nikki is also our Executive People Sponsor overseeing our Human Resources department. She holds a number of certifications in quality, regulatory, compliance, and human resources from the respective professional societies. Nikki began her career as a cytogenetics technologist before transitioning to Quality and then held various roles with increasing responsibility in organizations of various size and complexity. Nikki occasionally serves as an ad-hoc consultant for venture capital firms and small start-up clients. She holds an M.S. in Quality Assurance and Manufacturing from California State University, and a B.S. in Biochemistry, and a minor in Genetics from North Carolina State University.

Alyeska Investment Group, L.P. is the Chicago investment manager operating at alyeskagroup.com, founded in 2008 by Anand Christopher Parekh. Its legal identity is confirmed by SEC adviser registration CRD 155058 / file 801-71962 and institutional filing CIK 1453072. It manages a market-neutral long/short strategy and pooled investment vehicles. The manager is distinct from Alyeska Venture Management, Swiss Alyeska Advisors, and similarly named industrial or hospitality businesses. The March 23, 2026 SEC Form ADV names CEO Anand Parekh, CFO Jason Aaron Bragg and chief compliance officer Brent Metrick Cunningham. Separate fund-governance affiliations include external directors Christopher Bowring, Ebony Myles-Berry and Ruan van Vuuren. These external fund directors are not characterized as manager employees. The current filing describes Cayman Alyeska Master Fund, L.P. and two feeders: Cayman Aleutian Fund, Ltd. and Delaware Alyeska Fund, L.P. Its relevance includes an actual original Akili digital-neuroscience PIPE investment through Alyeska Master Fund, independently verified from original PIPE-issued shares and subscription price. Public-market holdings and later resale tables require separate qualification. Regulatory assets, gross asset values, minimum commitments and 13F holdings values are not newly closed fund capital. No undisclosed cash final close, personal founder check, or entire stock portfolio is inferred from management authority. The public manager website is a minimal contact page, so the recorded roster covers named primary regulatory/governance disclosures rather than an invented complete employee list.

Angie Fox has over 25 years of experience in clinical research in academia and industry, including over 12 years in the medical diagnostics industry. Angie joined Sera in November 2011 as the Director of Clinical Operations and served as Associate Vice President of Clinical Operations from 2017 to 2022. Angie has been responsible for developing and overseeing the Clinical Operations team and clinical quality management for several large and small multicenter-sponsored studies, as well as overseeing investigator-initiated projects with Sera. Before joining Sera, Angie was an Associate Director in Clinical Development and Medical Affairs at Pfizer in rare disease, and a Genetic Counselor and research coordinator in biochemical genetics and inherited metabolic disease focusing on lysosomal storage disorders at the University of Washington. Angie began her career in the laboratory, including a two-year technical predoctoral fellowship in the Laboratory of Molecular Biology, Section of Developmental Genetics at the National Cancer Institute. Angie holds a M.S. in Genetics and Biophysics from the University of Colorado Denver and a B.S. in Molecular Biology. She has been a Diplomate of the American Board of Genetic Counseling since 2002 and is a Certified Genetic Counselor licensed in the state of Washington.

Rob Harrison serves as an Information Technology Advisor to Sera Prognostics. During his tenure with the Company, including service as Chief Information Officer, he helped guide Sera’s technology strategy, infrastructure development, and information management initiatives. With more than 30 years of executive technology leadership experience, Rob previously served as Chief Information Officer at Myriad Genetics, where he played a key role in building the technology infrastructure that supported the company’s growth into a global precision medicine leader. He remains active in the technology community through organizations including the Utah Technology Council and AIM Utah CIO Council.

Dr. Paul Kearney serves as a Data Science Advisor to Sera Prognostics. During his tenure with the Company, including service as Chief Data Officer, he helped shape Sera’s data strategy and evidence-generation efforts. A recognized leader at the intersection of healthcare, data science, and innovation, Dr. Kearney has co-founded multiple biotechnology companies focused on oncology, pregnancy health, and food allergy, and has extensive experience in clinical research, bioinformatics, and product development. He has authored more than 100 scientific publications, is the inventor on more than 12 patents, and holds a Ph.D. from the University of Toronto.

Austin Aerts serves as a strategic advisor to Sera Prognostics, providing guidance on key initiatives and supporting operational continuity. Since joining the Company in 2017, he held multiple finance leadership roles, including Chief Financial Officer, and played a pivotal role in Sera’s successful initial public offering and transition to the public markets. Prior to Sera, he worked at Myriad Genetics and Ernst & Young LLP. Austin holds a Master of Accounting from the University of Utah and is a Certified Public Accountant licensed in the State of Utah.

Dr. Michael Foley is considered a national authority on Critical Care Medicine in Obstetrics. Before joining Sera, Dr. Foley practiced Maternal-Fetal Medicine in private practice for more than 20 years and recently retired from a 10-year role as Chairman of Obstetrics and Gynecology at the University of Arizona College of Medicine Phoenix/Banner University Medicine. He was the President of the Society for Maternal-Fetal Medicine (2008) and the recipient of the Society for Maternal-Fetal Medicine Lifetime Achievement Award (2013). He has also served as a Board Examiner in the subspecialty of Maternal-Fetal Medicine. Dr. Foley received his medical degree from Chicago Medical School in 1984. His Obstetrics and Gynecology residency and Maternal-Fetal Medicine fellowship were completed at The Ohio State University Hospital in 1988 and 1990, respectively. In addition to a long list of professional clinical accomplishments, Dr. Foley has a heart for giving back to the medical community. He is a founding instructor and faculty member for the Dan O’Keeffe, M.D. Society for Maternal Fetal Medicine’s Academy for Leadership and Development which is in its eighth year of training hundreds of medical leaders and professionals. Dr. Foley is also generous with his expertise, becoming an award-winning teacher and author. He is the Lead Editor of Obstetric Intensive Care: A Practical Manual (McGraw-Hill) which is currently in its fifth edition (2018). He is also a co-editor for Critical Care Obstetrics-Fifth and Sixth Editions (Wiley-Blackstone). We’re fortunate to access his medical leadership, a clinical prowess that is only matched by a passion for helping others.

Douglas Fisher, M.D. currently serves as a Strategic Advisor to Sera. He previously served as our Chief Business Officer from January 2015 to January 2022. Dr. Fisher served as a member of our board of directors from November 2011 to January of 2015 while he was a Partner a InterWest Partners LLC, a venture capital firm. Dr. Fisher led our Series A financing from InterWest in 2011. Prior to joining InterWest, Dr. Fisher served as Vice President of New Leaf Venture Partners LLC, a private equity and venture capital firm. Prior to joining New Leaf, Dr. Fisher was a project leader with The Boston Consulting Group, Inc., a global management consulting firm. He currently is a Partner at Revelation Partners, a healthcare focused venture firm. Dr. Fisher holds an A.B. and a B.S. from Stanford University, an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from The Wharton School of the University of Pennsylvania.

Benjamin G. Jackson has served as our General Counsel since April 2021. From February 2006 to March 2021, Mr. Jackson was employed by Myriad Genetics, most recently serving as Executive Vice President, General Counsel and Secretary. Mr. Jackson held various positions in Myriad’s Legal Department, including serving as associate general counsel prior to assuming the role of general counsel. Mr. Jackson received his J.D. from the J. Reuben Clark Law School at Brigham Young University and a B.S. in microbiology, immunology and molecular genetics from the University of California, Los Angeles.

John J. Boniface, Ph.D. has served as our Chief Scientific Officer since November 2011. Prior to that, Dr. Boniface briefly served as our Vice President of Research from September 2011 to November 2011. In his role as Chief Scientific Officer, Dr. Boniface is involved with our product development. Dr. Boniface previously served as scientist and program director for multiple biotechnology companies focused on protein discovery and small molecule and immunotherapeutic drug development, including Myrexis, Myriad Genetics, Prolexys Pharmaceuticals and Eos Biotechnology. Dr. Boniface holds a Ph.D. in Biochemistry from Albany Medical College and a B.S. in Biochemistry from the University of Massachusetts, Amherst. Dr. Boniface was a post-doctoral scholar in the laboratory of Dr. Mark Davis, Department of Microbiology and Immunology, Stanford University School of Medicine.

Scott Gleason is a diagnostics, life sciences, and healthcare executive with approximately 25 years of experience in finance, investor relations, corporate strategy, corporate communications, and equity research. Prior to joining the Company, he served as Vice President, Investor Relations and Treasury, of Neogen Corporation, an international food safety company. Before his role at Neogen, he served as the Chief Financial Officer of NX Prenatal, Inc., a prenatal diagnostic company, and LarmorBio, Inc., a Boston-based life sciences and clinical diagnostics startup. Prior to that, Mr. Gleason served as Interim Chief Financial Officer, Senior Vice President, Investor Relations and Corporate Communications of OraSure Technologies, Inc., a developer and manufacturer of diagnostic tests and sample collection solutions. Before joining OraSure, Mr. Gleason served as Senior Vice President, Investor Relations and Corporate Strategy for Myriad Genetics, Inc., a specialty diagnostics laboratory. Prior to Myriad Genetics, Mr. Gleason was a senior publishing analyst at Stephens Inc., where he covered the life science tools and diagnostics industry. Earlier in his career, he served as a United States Air Force aircraft maintenance officer. Mr. Gleason received a Bachelor of Science degree in Economics from the United States Air Force Academy in Colorado Springs, Colorado.

Dr. Tiffany Inglis is a board-certified Obstetrician Gynecologist with over 25 years of experience in direct care and the healthcare payer industry. In her role as Chief Medical Officer at Sera, she oversees clinical strategy, connecting research and development, clinical operations, data science, and commercial strategy. Her focus is ensuring that Sera’s products are backed by robust evidence and clear clinical value. Dr. Inglis provides enterprise-wide clinical leadership to align medical vision with corporate mission. Before joining Sera, Dr. Inglis was the Chief Medical Officer at Carelon Health, where she led evidence-based intervention programs supporting patient care navigation offerings. Prior to her time at Carelon, she served at Elevance Health, where she led a Commercial Health Plan, supported value-based care programs, and process improvement delivering population health initiatives. She specialized in using data to develop clinical program enhancements across lines of business and specialty areas. During her tenure, she helped redesign the Women and Children’s Health portfolio, build strategic solutions for multiple subspecialty areas, and led external partnerships focused on quality and value. Dr. Inglis earned her medical degree from the Medical College of Ohio. She holds a Bachelor of Science degree in Zoology, magna cum laude, from The Ohio State University, where she was also a collegiate volleyball player. In her free time, she enjoys spending time with her husband and two children.

Lee Anderson is a seasoned executive with over 30 years of experience in the biotechnology and diagnostic markets, including start-up companies with a focus on new product launches. Lee joined Genomic Health in 2004 as one of the initial commercial hires and held numerous leadership roles throughout his tenure, including Vice President of Sales and Global Customer Service. Upon Exact Sciences acquisition of Genomic Health in 2019, Lee served as the General Manager of the Precision Oncology business unit. Most recently Lee was the Chief Commercial Officer of Biofidelity Inc. Lee has successfully built and led high-performing commercial teams that have consistently exceeded their goals. His commercial experience includes leading sales, customer service, strategic accounts, commercial learning, and marketing teams. In addition, he has experience with acquisitions and divestitures, setting corporate strategy and vision, portfolio management and creating and ensuring cross-functional team environments. Lee also founded a life sciences consulting company, providing commercial strategy for start-up companies looking to secure capital investment. In addition to his corporate roles, Lee served as an advisory board member for the Department of Biological Sciences at Florida State College where he was instrumental in creating the Bio-Medical Science degree that is now offered at the institution. Lee holds a Bachelor of Science in Biology with a minor in Chemistry from Florida State University, magna cum laude.

Zhenya Lindgardt is the President and CEO and a Board Director of Sera, Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients. Prior to joining Sera first as a Board Director in 2021, Zhenya was a member of Executive Leadership team and a C-level executive at Uber Technologies, Inc. in charge of creating new long-term growth businesses on Uber platform, customer engagement and cross-sell across core businesses. In her role at Uber, Zhenya focused on incubating new and scaling current Uber’s two-sided marketplaces and services, driving experimentally proven incremental growth through customer retention and engagement (including cross sell, personalization, portfolio of loyalty programs, subscriptions) across all customer groups. Before Uber, Zhenya spent 19 years with the Boston Consulting Group (BCG) where she held several operating leadership roles as a Senior Partner and Managing Director of the firm. She was a leadership team member of the largest region (North America, >$5B in revenue) and practice area (Corporate Finance & Strategy, largest for BCG). In healthcare, one of Zhenya’s core areas of focus at BCG, she has worked across the full healthcare industry spectrum from R&D based biopharma and biotech, biomaterials to integrated healthcare systems, pharmacy benefit managers, payers and providers. Breadth of her knowledge of operations of each of these businesses spans from all aspects of operations, as well as corporate, therapeutic area/service line and portfolio strategy and M&A. Therapeutic areas she has expertise in include gene therapy, rare diseases, HIV, oncology, women’s and men’s health, vaccines, ophthalmology, endocrinology and cardiovascular among others. Zhenya also serves as the CEO of The Commons Project Foundation since 2021, focusing on modernizing industries enabling with their data, starting with health. One of TCP’s flagship products, CommonHealth, is a platform for individuals to access and share all their health data, including wearables, to share with their physicians and family. Broader ongoing monitoring and deploying insights from latest innovations will help clinicians to deliver better quality care and lower overall healthcare costs. Zhenya received an MBA from Harvard Business School and a bachelor’s degree, cum laude, from the University of Southern California. She lives in San Francisco with her husband and three daughters.

Eleanor Coffey advises Vulpes Life Sciences with expertise in molecular neurobiology, synaptic plasticity, protein trafficking and stress signaling. The own biography describes research leadership at Turku Bioscience Centre and work on brain protein kinases relevant to neurodegenerative and neuropsychiatric disorders. Clinical approval or therapeutic validation is not inferred from this research.

Wilson Er is identified as Vulpes Chief Investment Officer in the March 30, 2026 SEC Form ADV, with appointment month August 2025. This regulator-supported leadership appointment is absent from the public website roster. His biography and portrait require further independent primary material; no broader career details are inferred.

Martin Shenfield is named in the Vulpes senior advisor and non-executive director directory without a precise published governance capacity. His experience spans global asset allocation and institutional, mutual, UCITS and hedge-fund mandates, including Morgan Grenfell, Fidelity and TT International. His regional experience includes Asia-Pacific and emerging markets, and he advises family offices and EIS funds.

Geoffrey Flynn is named in the Vulpes senior advisor and non-executive director directory without a precise published appointment title. His career included securities and money brokerage, international Reuters leadership and CEO of Instinet Asia Pacific. He retired from that operating career in 2002 and established property-restoration businesses in Italy.

Will Garner is named in the Vulpes senior advisor and non-executive director directory, without a precise published capacity. His background includes financial research, investing and immigration law. He studied finance at Georgia, law at Nevada Las Vegas and business administration at Florida and completed Stanford executive education. Outside corporate titles in the biography require separate current verification.

Grant Williams is named in the Vulpes senior advisor and non-executive director directory; the precise capacity is not published. His biography describes trading experience across Asian equities and derivatives, including Robert Fleming, UBS, Credit Suisse and Jefferies in London, Tokyo, New York, Hong Kong, Sydney and Singapore. Historical trading roles are not treated as current employment.

Glenn Blasius is named in the Vulpes senior advisor and non-executive director directory, which does not identify his precise governance capacity. His career covers fixed-income credit portfolio management, trading and risk, including Antarctica Capital, Christofferson Robb and Company, Bear Stearns and other investment banks. He studied Engineering Physics at Cornell.

John A. Dawson, CBE, consults for Vulpes Life Sciences. He formerly led Oxford Biomedica for thirteen years, overseeing growth of its viral-vector cell and gene-therapy business and vaccine manufacturing work. His earlier roles include Cephalon and Serono. He is a Chartered Accountant and studied mathematics at Swansea. Outside board positions mentioned in the manager biography are not independently promoted to current appointments.

Teodoro Guarini manages the tail-hedge book and works on the AI-driven long-short equity sleeve of the Vulpes VaiL/S Tail Risk strategy. He joined in 2026 after more than five years with Eurex at Deutsche Borse, including derivatives clearing in Frankfurt and Asian-hours control in Singapore. His degrees are from Naples Federico II and Naples Parthenope, with an exchange term in Frankfurt.

Anthony Diggle joined Vulpes in 2013 with responsibility for agriculture and German property. Earlier consulting included investment diligence in agriculture, residential property and natural resources. His current role focuses on tangible assets and oversight of agricultural operations. He studied American and European Studies at Derby and Information Studies at Brighton.

Tam Seen Yee manages financial and management reporting at Vulpes. Previously she worked in auditing at a Big Four firm. She studied accountancy at Nanyang Technological University.

Jamie Diggle is a financial analyst at Vulpes focused on biotechnology and demographic investment research. He earned a Business Science degree specializing in finance at the University of Cape Town. His own biography describes completion of CFA Level 2, not a fully earned CFA charter.

Ana Gomes leads communications and investor relations at Vulpes, including research, public relations, branding and content. Her underlying biography also uses Corporate Communications Manager. Previously she worked in market research at Sands China in Macau. She studied Chinese and Economics at Edinburgh and Development Studies at Cambridge and speaks English, Portuguese, Mandarin and Cantonese.

Kim Ivey advises Vulpes with experience in private banking, asset consulting, risk oversight and quantitative portfolio management. Earlier employers include Merrill Lynch, Citibank, Towers Perrin and Commonwealth Bank. He founded Vertex Capital Management in 1998 and has held industry and charitable governance positions. Previous employer asset totals and charitable receipts are not Vulpes capital raised.

Philipp von Bernstorff manages special situations and turnaround investments at Vulpes and serves on the Testudo Fund investment committee. The own directory spells his surname Bernstoff while its biography uses Bernstorff; both refer to this same profile. He joined in 2012 after managing the Russian Opportunities Fund at Artradis and working in Moscow equity sales, trading and proprietary trading. He studied at MGIMO and Staffordshire University.

Alistair Nicholson manages agriculture investments and is Executive Chairman of Vulpes Agricultural Land Investment Company. He has invested in New Zealand farming since 2004. Previous positions include Alcor Investment Management CEO, Jardine Fleming New Zealand country leadership and equity trading and derivatives at Lehman Brothers in Hong Kong. He studied economics at Massey University.

Nicholas Robert Thibeault directs business development across the Vulpes platform and is a director in the March 2026 SEC filing. Earlier work includes investment management and banking at Canaccord Genuity, corporate advisory in Myanmar and fintech country leadership. He joined Vulpes in Singapore in 2019 and studied Economics and Politics at the University of Bath.

David Mackey is a Vulpes portfolio manager and CEO of Stronghold Capital. His career covers real-estate investment banking, REIT management and funds. Previous positions include corporate and strategy leadership at LMIRT, regional real-estate leadership at RBS, corporate finance at HSBC and institutional property research. He studied economics at the University of Tasmania.

Stuart Merrilees is COO of the independent UK operating company under the Vulpes brand. His work emphasizes operational efficiency and regulatory compliance. His background spans institutional investment management, capital markets and engagement with growing technology companies. He graduated from Newcastle University.

Sadiq Currimbhoy advises Vulpes on sustainability, developing investment ideas and assessing how businesses adapt to a low-carbon economy. Earlier roles include research and sustainability leadership at Maybank Kim Eng, investment strategy at Merrill Lynch and global strategy at NewSmith. He studied economics at the London School of Economics and University of Pennsylvania and sustainable business at Cambridge.

Bert Verdicchio is Vulpes Treasurer. His experience covers risk management, capital commitments and financial engineering across fixed income, credit, equities, currencies and derivatives. He has managed liquidity and working capital for Vulpes and its family-office sponsor, including borrowing arrangements, disposals and recoveries. He graduated from Yale.

Kirti Rani leads technology at Vulpes. Since joining in 2011 she has managed IT infrastructure and vendor-supported user services. Her earlier work was in software development. She holds a Masters in Computer Applications from Banasthali Vidyapith in India.

Chee Seng Ng joined Vulpes in 2019 after fund-accounting work at Citco and a controller position at Alphadyne, now Astignes Capital Asia. He studied Banking and Finance at the University of London. The current own directory calls him Chief Operations Officer; both MAS and the March 30, 2026 SEC filing identify him as Singapore Chief Executive Officer, and SEC also identifies Chief Compliance Officer. These jurisdiction-specific regulatory titles are distinguished from the UK CEO.

Jasmine Zhang is listed in the current Vulpes directory as Operations Consultant. Her underlying biography describes an earlier or inconsistent Chief Financial Officer title, joining in 2013 and overseeing financial affairs from 2019; this is retained as a source discrepancy rather than a second unqualified current appointment. Her background includes fund administration and asset-management finance. She studied accountancy at Nanyang Technological University.

William Overlock Crispin is Vulpes chief legal officer and a director identified in its March 2026 SEC filing. His legal work covers investment funds, private equity, corporate transactions and joint ventures across Asia-Pacific, the US, UK and Cayman Islands. He studied at Washington and Jefferson College, Pittsburgh School of Law, Boston University School of Law and Warwick Business School.

Stephen Charles Diggle founded Vulpes after the closure of Artradis Fund Management. He manages life-sciences investments and became CEO of the independently operated UK company in September 2024. His career began in finance in 1986 and includes investment-banking work in London, Sydney and Hong Kong. He studied Philosophy, Politics and Economics at Oxford. Artradis historical assets and profits are not Vulpes fundraising.

Chao Wu is vice president and head of ABB Group Ventures. ABB’s current native venture-directory model lists him in the group-level leadership section, distinct from the business-area Electrification and Motion teams. This profile represents that corporate venture executive and authentic ABB portrait, without assuming a same-name academic or technology professional.

Rayann Barazi is a ventures analyst at ABB Motion Ventures. He is part of the venture team supporting ABB’s Motion business and its industrial performance, energy efficiency and digital technology investments. ABB’s own directory identifies his exact role and authentic portrait.

Olga Peters heads ABB Motion Ventures, the venture and open innovation arm of ABB’s Motion business. Its mandate covers next-generation electric machines, power electronics and semiconductors, industrial AI, electrification and circular technologies. Her current title and authentic named portrait are published by ABB.

Analia Troncoso is ABB Motion’s global head of strategy, business development and sustainability. ABB includes her in its Motion Ventures directory as a business-area leader supporting the corporate venture and open innovation framework. The role concerns ABB’s drives, motors, powertrains and industrial performance business; no independent fund-management or personal-investor role is inferred.

Lukas Odelberg is an investment analyst at ABB Electrification Ventures, according to the latest live native ABB team directory and model downloaded in October2026. The business-area venture team focuses on electrification and industrial energy technologies. Earlier cached directory text naming a different analyst is not treated as his biography or evidence of that person’s current tenure.

Fatima Ben Larbi is an open innovation specialist in ABB Electrification Ventures. She works in the business-area venture and startup collaboration team, supporting links between emerging technology companies and ABB’s industrial expertise. ABB’s current named directory provides her role and authentic portrait.

Alexander Kolloge is an investment manager at ABB Electrification Ventures, supporting the business-area venture investment and startup collaboration program. Its published mandate includes next-generation power infrastructure, industrial energy systems and AI-driven energy optimization. His role and authentic portrait are confirmed by ABB’s own directory.

Cal Stock is an investment principal at ABB Electrification Ventures. He works within ABB’s corporate venture platform focused on scalable electrification, energy and industrial technology companies. ABB’s official directory identifies his exact role and named portrait; the same-name Vectr Solutions professional is not assumed.

Mads Møller is vice president and head of ABB Electrification Ventures. He leads venture investment and industrial collaboration within ABB’s electrification business, which backs technologies in grid modernization, DC power systems, AI-driven energy optimization and intelligent buildings. His current role and portrait are published in ABB’s official venture directory.

Tom Lambert is published by Phoenix Court as Partner, Investment, in its investment function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Ziv Reichert is published by Phoenix Court as Managing Partner, Investment, in its investment function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

ABB Technology Ventures (ATV), currently branded ABB Ventures, is ABB Group’s business-led corporate venture capital framework for breakthrough industrial electrification and automation technologies. Founded in2009, it invests in robotics, industrial IoT, AI/machine learning, energy transition, cybersecurity, sustainability, electric mobility, smart buildings and distributed energy. ABB Ventures comprises business-area activities including Electrification Ventures, Motion Ventures and Robotics Ventures, with ABB Group Ventures leadership. Its current website reports aroundUSD500 million deployed since formation; that cumulative investment figure is not a closed LP fund or currently available budget. The framework invests primarily in SeriesA andB companies and offers industrial expertise, R&D, global customer access and technical/commercial collaboration. Its current native directory publishes nine named professionals across the group, electrification and motion activities; the latest live page lists Lukas Odelberg as analyst, whereas older cached versions listed Manuel Elter. No parent-wide workforce or unsupported historical leadership is asserted as the venture team. Authentic named portraits and ABB’s own published wordmark are used. Verified portfolio examples include AI processor company Hailo, laboratory robotics company Automata, surgical robotics company CMR Surgical, drone intelligence company Kespry and energy AI companies BrainBox AI and Ndustrial; portfolio status and transactions require their own source qualifications. ABB Technology Ventures and the parent ABB corporate subscriber are represented at framework level without inventing the precise legal bank-account payer of each check. This profile is distinct from the contaminated historical SmedvigCapital3413 record, Smedvig Capital and independently raised third-party VC funds. Individual investment tickets and fund allocations are undisclosed unless a specific primary source proves them.

Play Ventures is an early-stage venture capital firm investing globally in game studios, consumer applications, and related technology infrastructure. Its strategy includes mobile free-to-play games, consumer apps that use game mechanics, developer platforms, artificial intelligence tools, advertising technology, and payment services. Founded by gaming entrepreneurs, the firm can invest before products launch and supports founders with product and game design, recruitment, fundraising, and connections across its portfolio and industry network. Its team operates across Singapore, Helsinki, and other gaming and technology hubs.

X2 Equity is a private technology investment holding company that builds and backs hardware and business software companies in Europe and North America. It invests its own capital generated through previous entrepreneurial activities, rather than operating a conventional externally funded venture capital model. Its focus includes industrial systems, sensors, semiconductor manufacturing, data platforms, and software using machine learning to improve operations. It provides hands-on support with product development, commercialization, operational improvements, international expansion, and restructuring, with investments ranging from early prototypes to growth and turnaround situations.

Chris Kim (published Korean name 김동준) is a principal at Atinum Investment. He joined in 2025 after working as a gaming and entertainment analyst at CLSA Korea.

Robin Klein co-founded Phoenix Court and is a current board member, included in the investment function. The manager’s own2021 narrative distinguishes his mentoring and support for existing Latitude companies from leading new investments. This profile records current shared-platform governance and investment experience, without inventing an executive appointment or personal check.

Sam Warren is published by Phoenix Court as Partner, Value Creation, in its value creation function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Remus Brett is published by Phoenix Court as General Partner, Investment, in its investment function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Rashad Mohammed is published by Phoenix Court as Director, Legal, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Rajeelan Thayalaseelan is published by Phoenix Court as Partner, Finance, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Paul Bishop is published by Phoenix Court as Managing Partner, Finance and Investor Relations, in its business operations, investment function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Nuno Campos is published by Phoenix Court as Partner, Technology, in its investment function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Nin Pandit is published by Phoenix Court as Managing Partner, Value Creation, Special Projects, in its value creation function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Mbali Mbatha is published by Phoenix Court as Partner, People, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Nick Malkewitz is published by Phoenix Court as Associate, Spaces, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Max Pavier is published by Phoenix Court as Partner, Talent, in its value creation function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Matt Peplow is published by Phoenix Court as Partner, Legal, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Laura Pospiech is published by Phoenix Court as Director, Spaces, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Kira Jang is published by Phoenix Court as Partner, Finance, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Judith Stephenson is published by Phoenix Court as Executive Assistant, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Jacob Hinton is published by Phoenix Court as Associate, Value Creation, in its value creation function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Emilie Spire is published by Phoenix Court as Partner, Special Projects, in its value creation function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Ben Adler is published by Phoenix Court as Partner, Finance, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Darren Shapland is published by Phoenix Court as Non-Executive Director, in its board function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Dave Kashen is the published founder and partner of Fearless Ventures and an executive coach. He founded Worklife, acquired by Cisco, and Wellsphere, acquired by HealthCentral; his manager biography describes prior investing at SPO Partners and investment banking at Goldman Sachs. He earned an MBA at Stanford and a BS in economics at Wharton. His own current coaching website documents continued work with startup founders; clients are not inferred to be Fearless portfolio investments. December2025 SEC venture-SPV filings confirm his legal management alongside Seth Miller.

Diana Barran is published by Phoenix Court as Non-Executive Director, in its board function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Ambi Mistry is published by Phoenix Court as Partner, Portfolio Experience, in its business operations, investment function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Amy Grimshaw is published by Phoenix Court as Partner, Marketing, PR and Communications, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Allan Nixon is published by Phoenix Court as Chief of Staff, in its business operations function. Phoenix Court operates the LocalGlobe seed, Latitude breakout and Solar scale-stage strategies through a shared platform. This directory establishes the named platform role; it does not independently establish a separate Latitude employment contract or personal investment check.

Don’t Quit Ventures is a solo-GP venture firm founded by Noa Khamallah investing at pre-seed and seed. It offers initial investments of USD50,000–150,000 and operator support with commercial strategy, public relations and networks, emphasizing access for founders who face barriers in conventional venture fundraising. Its disclosed holdings span frontier AI, software development, cybersecurity and transport infrastructure, including Thinking Machines Lab, AMI Labs, Replit, Huskeys and The Boring Company.

Mamor Capital Ventures is a South African venture capital manager backing post-revenue businesses in payments, telecoms, digital trade and sustainable technology. The black women-owned and managed firm combines investment capital with strategic and operational support. Its published strategy covers broadband, IoT and 5G infrastructure; payment systems and security; digital marketplaces; and technologies improving energy, water, waste management and agriculture. It targets early growth and pre-Series A investments of ZAR6–27 million.

Ayanda Ngcebetsha brings experience in data analytics, artificial intelligence, cloud computing and telecoms infrastructure. Mamor identifies him as a chief data officer at Microsoft.

Chris Lister James is a technology startup investor with experience completing venture capital transactions and successful exits.

Fuzlin Levy-Hassen is a chartered accountant with more than 25 years in venture capital, private equity and development finance. Her experience includes fundraising, origination, diligence and portfolio support, with previous investment leadership at IDC and the National Empowerment Fund.

Ian Ziddah has more than 20 years in telecoms and technology commercialisation. His experience includes product development at MTN Ghana, co-founding payments company M-Pay and evaluating and monitoring early-stage venture investments.

Liesl Mckay founded Tribel Consulting and previously led Rand Merchant Bank’s Foundery technology initiative. She advises startups on strategy and growth and mentors women founders.

Lindani Kgosietsile holds a master’s degree in financial economics from the University of Leicester. She previously worked at Stanbic Bank, Grant Thornton Botswana and Marlow Capital, supporting portfolio growth, operations and exits.

Mamokete Ramathe founded Mamor Capital after more than 20 years in investment banking, corporate finance, private equity, infrastructure and M&A. She previously led mergers and acquisitions at Vodacom Group and co-founded infrastructure business Vulatel.

Moses Mufunguri has more than 15 years of experience in finance, consulting, telecoms, technology and fund management across East and Southern Africa, including work at Danoffice IT, Comtel Integrators Africa and Awethu Project.

Noa Khamallah founded Don’t Quit Ventures after operating and building micromobility businesses. Allocator One identifies him as Lime’s first hire in Europe and a co-founder of GetCharged, later acquired. He runs DQV as its sole general partner.

Shadi Chauke is a chartered accountant and media executive with more than 15 years in financial services. A former Deloitte South Africa partner, she owns and produces through Viva Pictures and Pop Up Media.

Fearless Ventures is a San Francisco venture investment firm founded by Seth Miller and Dave Kashen. Its own website identifies the brand as Fearless Ventures, LLC. The firm pairs investment with CEO coaching, conscious leadership training and support for companies creating value for their stakeholders. Miller previously served as a general partner and investment committee member at DBL Investors. Kashen founded Worklife and Wellsphere and coaches startup founders. These two partners comprise the complete publicly named team retrieved; their undated website biographies retain a 2017 copyright and do not establish a larger current staff roster. December 2025 SEC filings independently confirm both partners as managers of the managing member of venture SPVs administered by Fearless SPV Management, LLC. The brand company and this legal SPV manager are distinguished rather than assumed to be the same entity. Its neuroscience investments include Akili’s 2018 Series C extension and 2021 Series D for cognitive digital therapeutics. Four associated Devoted Health, Function Health and CFS venture SPVs are supported by primary legal filings. Reported fund subscriptions are qualified snapshots, not verified final closes or portfolio company tickets. No flagship final close or AUM is verified. This firm is distinct from Fearless Fund and other similarly named companies. The unfinished template content and example logos on its portfolio page are excluded from investment claims.

Seth Miller is the published founder and partner of Fearless Ventures. His own manager biography describes more than a decade at DBL Investors, most recently as general partner and investment-committee member, and earlier environmental-policy work for the White House and US Senate. He studied at the University of Pennsylvania and earned law/MBA degrees at Northwestern. The DBL225million across two historical funds belongs to DBL, not Fearless. Fearless’s undated biography also names a Maiyet chair role, which is not asserted independently current. December2025 SEC venture-SPV filings confirm current legal management alongside Dave Kashen.

Professor Julia Sutcliffe is an external Innovate UK Council member. Her UKRI biography identifies her as Chief Scientific Adviser at the Department for Business and Trade, not an Innovate UK employee with that title. Her background includes BAE Systems engineering and technology leadership.

John Patterson is an external Innovate UK Council member. His UKRI biography describes chairing software company 2iC, advising technology businesses and UK Innovation and Science Seed Fund, and earlier British Army and defence technology leadership.

Tunde Olanrewaju is an external Innovate UK Council member. His UKRI biography describes his McKinsey background advising organisations on digital transformation, analytics, strategy and operations. Outside employer titles in the older individual biography are source-attributed.

Annalisa Gigante is an external Innovate UK Council member. Her UKRI biography describes advisory and board work spanning advanced materials, enterprise investment, deep technology and AI, alongside a career leading innovation across international businesses. Cambridge Enterprise affiliation: Annalisa Gigante is listed by Cambridge Enterprise as External Non-Executive Director. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

John Gibson is an external Innovate UK Council member. His May 2026 UKRI biography describes his commercial leadership at AI company Faculty and earlier government, Nesta and Fingleton Associates work on innovation, automation and open banking.

Chris Ganje is an external Innovate UK Council member. His published UKRI biography describes co-founding and leading AMPLYFI, which uses machine learning for business intelligence, and earlier technology, strategy and operations work at BP. The biography’s outside employer titles are attributed to that source.

Scientist, entrepreneur and investor Harry Destecroix is an external Innovate UK Council member. His UKRI biography describes founding Science Creates and SCVC, leading smart-insulin company Ziylo to its 2018 acquisition, and co-founding glucose-sensor company Carbometrics.

Boryana Stambalova is listed by Innovate UK as Director Finance on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Dave Wilkes is listed by Innovate UK as Director Innovation Infrastructure on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Guy Woolley is listed by Innovate UK as Chief Operating Officer on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Pixl Bio combines human stem-cell-derived models, automated laboratory experiments and AI analysis to help pharmaceutical researchers study disease, drug responses and toxicity. Its products include hepatocytes, stellate cells, organoids and engineered disease models, alongside cell-painting microscopy and custom experimental services. The company uses image-based phenomics to measure cellular changes and turn them into predictions and mechanistic insights. Formed through Phenaros’s acquisition of DefiniGEN in July 2025, it brings together AI and automation capabilities in Uppsala with cell-biology expertise in Cambridge. Its planned pixlOS software connects experimental data, research workflows and predictive models.

Claire Spooner is listed by Innovate UK as Director Innovation Service on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

RNatives develops investigational RNA medicines that regulate gene expression to address serious diseases. Its RNAIntel platform uses artificial intelligence, machine learning and genomic datasets to find small non-coding RNAs that can activate or silence genes, then validates selected candidates in laboratory experiments. The Finnish biotechnology company is developing precision therapies for ocular and metabolic diseases and cancer, with earlier published work also discussing cardiovascular and central nervous system applications. The underlying research uses RNA interactions to induce epigenetic changes that can have lasting effects on gene expression.

Rob Saunders is listed by Innovate UK as Director Clean Energy on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Fran McIntyre is listed by Innovate UK as Managing Director, IUK Business Connect on its official July 2026 Executive Leadership Board directory. Her role leads the Business Connect delivery unit; this is distinguished from private fund management.

Scott O’Brien is listed by Innovate UK as Director of Innovation Finance on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Gary Cutts is listed by Innovate UK as Director Digital and Technologies on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Sarah Goulding is listed by Innovate UK as Director Life Sciences on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Dean Cook is listed by Innovate UK as Director Business Growth & Global on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Sarah Bell is listed by Innovate UK as Director Business Engagement Strategy on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Bruce Adderley is listed by Innovate UK as Director Advanced Manufacturing on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Kath Mackay is listed by Innovate UK as Interim Managing Director on its official July 2026 Executive Leadership Board directory. The directory establishes the published agency role; additional career details and appointment dates are not inferred.

Entrepreneur and board director Tom Adeyoola is Innovate UK’s Executive Chair. His agency biography describes his Cambridge education, founding Metail, supporting Elvie and Verco, and co-founding Extend Ventures. These career affiliations are biography context, not additional institutional financing checks.

Beijing Chongde Yingsheng Investment Management is a Beijing venture-capital fund manager focused on innovative medicines, medical devices, research and development services and biotechnology. It manages Beinao I, a specialist neuroscience fund investing in next-generation diagnostics, treatments, medical equipment, consumables and drugs for brain disorders. The firm also manages the separate, older Beijing Chongde Yingsheng Venture Capital vehicle.

Annie Santos was explicitly identified as Head of Ventures Operations in Murali Venkatesan’s first-hand2024 account of the Danaher educational visit, reproduced in Charlie Purtell’s own public post. This is a dated operational affiliation rather than confirmation of continued employment inOctober2026; exact tenure dates, biography and authentic individual portrait remain undisclosed in the reviewed source. Unrelated same-name automotive and community professionals are not merged.

MAGENTIQ EYE develops AI decision-support software for gastrointestinal endoscopy. Its MAGENTIQ-COLO platform analyzes live colonoscopy video and flags suspected polyps to help endoscopists detect lesions that might otherwise be missed. The platform also detects endoscopic tools; its European version adds polyp size estimation and characterization, bowel-preparation scoring, cecum detection and structured procedure reports. The company is developing further tools for upper gastrointestinal and inflammatory bowel disease procedures. It operates as MAGENTIQ-EYE Ltd., founded in Haifa in 2014.

Ultromics develops AI software that analyzes routine echocardiograms to help clinicians identify heart failure with preserved ejection fraction and screen for cardiac amyloidosis. Its EchoGo Heart Failure and EchoGo Amyloidosis products evaluate cardiac ultrasound images, generate disease-related findings and probability scores, and deliver results through existing hospital imaging workflows. The Oxford University spinout combines cardiovascular research and machine learning to support earlier assessment and treatment pathways, using secure cloud integration with ultrasound systems and PACS.

Ultromics COO leading strategy, operations and business development. Previously led Philips’ global cardiology informatics business and enterprise integration services. Holds an Imperial College chemical engineering MEng and an INSEAD advanced management certificate.

Ultromics chief product officer, formerly its head of R&D. Previously developed diagnostic technologies at Perspectum, Oxford University Hospitals and GlaxoSmithKline. His experience includes diagnostics, intellectual property and technology transfer.

Ultromics chief regulatory and compliance officer. Previously led regulatory compliance at Perspectum across multiple international markets. Holds an Oxford doctorate in safety-critical systems design.

Ultromics chief experience officer leading service operations and customer experience. Previously led operations at Oxford’s Cardiovascular Clinical Research Facility and delivery of the EVAREST echocardiography study. Holds chemistry degrees and a toxicology doctorate focused on metabolic biomarkers.

Mayo Clinic cardiovascular medicine leader and clinical research collaborator whose echocardiography expertise contributed to development and validation of EchoGo. Ultromics’ own About page describes her collaboration; it does not identify her as an employee, director or formal advisory-board appointee.

Academic founder and non-executive director, according to his own current Ultromics biography. Professor of Cardiovascular Medicine at Oxford; established its Cardiovascular Clinical Research Facility in 2009. His research generated intellectual property underpinning Ultromics. The separate leadership roster still calls him chief medical officer; that source discrepancy is retained in the evidence map.

Ultromics chief commercial officer leading global commercialization. Previously held cardiovascular device roles at Guidant, Boston Scientific, Abbott and Cardiva. Holds biomedical science, psychology and cardiac physiology degrees from Ohio University.

Ultromics founder and CEO. His Oxford doctoral research with Paul Leeson produced the echocardiography AI technology behind the 2017 spinout. He has led EchoGo development and the company’s growth into clinical cardiovascular imaging.

Blue Venture Fund associate and published Ultromics board observer. Previously worked in finance and commercial strategy at Becton Dickinson and interned at JJDC and Joyance Partners. Holds a Chicago Booth MBA and a Brigham Young accounting degree. The observer role does not imply a personal investment or a board director seat.

Samuel Ngai represented Danaher Ventures as Asia head and Vice President of Science and Technology at the LINK-J event on19July2024. The2025 BIO Korea programme and organizer Benelux Chamber seminar explicitly call him former head of Danaher Ventures Asia. The2024 affiliation and authentic named event photograph are historical; a precise departure date and current Danaher employment are not asserted. He is distinct from same-name civic and social-service professionals.

Charlie Purtell is named Vice President of Danaher Ventures in the2026 BioInnovation Group Executive Summit organizer agenda. His own2026 public post discusses AI-driven drug discovery and Danaher’s investment partnership in Automata; a2023 first-hand Murali event post also identified him as the venture unit’s vice president. No personal investment ticket, exact employment start or unverified headcount is inferred.

Alex de Winter invests in life sciences tools and diagnostic startups for Danaher Ventures. His Berkeley Haas first-hand2022 profile calls the unit Danaher Equity Ventures and his PMWC2024 speaker biography identifies him as Vice President of New Ventures, following GE Ventures, Mohr Davidow, Pacific Biosciences and454LifeSciences. The published RESI conference judge roster retains the Danaher title. These dated public affiliations support the unit relationship, without an invented exact appointment day.

Danaher Ventures is Danaher Corporation’s corporate investment subsidiary, identified as Danaher Ventures LLC in the parent’s own transaction announcements. Established in2017, it finances and develops early-stage businesses in biotechnology, diagnostics, scientific tools and data science. It supports investment partnerships and venture creation through the Pioneer Program, combining corporate capital and operating expertise. These operating mechanisms are not evidence of separate outside-LP funds or a cash fund close. Its verified AI-related investments include Automata’s robotic laboratory infrastructure and Innovaccer’s healthcare data and AI platform; primary sources also identify BlueWhale Bio’s cell-therapy manufacturing work and Signify Bio’s nucleic-acid protein therapeutics. Portfolio affiliations do not establish present ownership or undisclosed ticket sizes. The parent corporation, academic research collaborations, subsidiary instrument businesses and venture unit are distinguished. Leadership is date-qualified: Murali Venkatesan’s own recent departure announcement supersedes the website’s continuing head label, while Samuel Ngai is explicitly a former Asia head in2025 organizer sources. Other recorded affiliations retain their published dates. No successor, complete current staff directory, external-LP final close or unit-wide capital total is verified. The logo is the authentic Danaher wordmark used on the unit’s own webpage.

Allen is a successful entrepreneur and experienced corporate executive in the healthcare and medical informatics space.

Avi is General Partner at OurCrowd First, israel’s most active early-stage venture fund, seeding and scaling high-tech companies that are computing and actuating the connected world.

Christoph is an entrepreneur and venture capital expert with a passion for early-stage startups and sports.

David is responsible for New Business Relations and Account Management with Investors from LATAM.

Eduardo Shoval has over 25 years of experience as a serial entrepreneur, angel investor and mentor in high-tech management, with a proven track record steering companies through the challenging stages of rapid growth.

Before joining OurCrowd, Gilad worked as an investment manager at Psagot Mutual Funds, overseeing various mutual funds targeting different sectors and regions, managing a $80 million portfolio.

Jay Kalish has extensive legal, investor relations and management experience over the past 20 years.

Jeremy is Israel’s only active venture capitalist and professional basketball player, a unique combination for leading a sports tech investment fund.

John has been a venture investor for over 20 years.

Over John’s 20+ year career as a venture investor, he has been a founder of Blacksmith Capital and True Ventures, both of which were defined by his passion for early-stage investing and growing companies.

Kirk Haney is the Co-Founder & Managing Partner at Radicle Growth.

Orly Wolynetz is the project manager for the OurCrowd funds team.

Thanasis has been a venture investor for 19 years.

Yori Nelken is a serial entrepreneur and angel investor with over 18 years of leadership experience driving startup companies from concept to success.

Dr.

Alan is leading the development of OurCrowd's presence in Hong Kong from a licensing and regulatory perspective, as well as working on the maintenance and expansion of investor relations in Hong Kong and Asia.

Amit Almog is an Account Manager at OurCrowd, with a background in financial planning, trading, and sales.

Joined IBM Ventures after five years leading strategy and transactions at IBM Research; current participation corroborated by June 2026 first-person interview.

Andrew brings extensive experience in investment management strategy, operations, and acquisitions to SoftBank.

Own 2026 posts document IBM Ventures portfolio development, hiring and events; external databases suggest Partner but that precise title lacks own public confirmation.

Ben Plotkin is the Vice Chairman, Stifel Financial Corp.; Executive Vice President, Stifel, Nicolaus & Company, Inc.; and Executive Vice President, KBW.

Publicly named by BQPhy founder alongside IBM Ventures investment team; third-party Principal title is not used without primary confirmation.

Own 2026 announcement confirms transition from IBM M&A into venture investing and portfolio development.

Daniel is an Account Manager at OurCrowd, working with clients across Europe and APAC.

Daniel Ivanov started his career as an Investment Strategist at Pilgrim Asset Management, a hedge fund with over $200M AUM, before joining JSCapital, an investment bank that founded the Israeli Blockchain Association (where Daniel was a Board Member) and VentureIsrael (VC).

Publicly named as head of strategy for IBM Ventures in April 2026.

David serves as Partner of Investor Relations in Toronto, breaking new ground for OurCrowd and startup investing in Canada.

Originally from England, Eli made Aliyah in 2013.

Ely Razin is a seasoned FinTech leader and investor, with extensive experience as both entrepreneur and as senior executive in the large corporate world.

Leads IBM venture investments, enterprise AI and quantum strategy, and startup commercialization.

Originally from Argentina, Gustavo made Aliyah to Jerusalem in 2021.

Hilton serves as an advisor to Bangkok Bank PCL since 2002. He spent 14 years with Citibank Europe/Africa Div and Asia Pacific Div ; A/P Consumer Bank Division Treasurer. Prior to that he managed Visa Australasia through the ‘90s.

Jeff Khoury is Vice President of Investor Relations at OurCrowd, leading the global Account Management team responsible for investor engagement and fundraising across venture capital and other alternative investments.

Kiyoshi Habiro is the CEO of ORIX UK and Europe.

Named by IBM colleague as IBM Ventures team member at current Boston Open Accelerator event; unrelated namesake public profiles are not reused.

Publicly named at IBM-sponsored April 2026 corporate venture session.

Priyanka works as an Associate Director out of the Toronto office and is responsible for the Eastern region of the United States.

Rousselle Banza is an Account Manager at OurCrowd, bringing over six years of experience across private capital markets, with a strong foundation in private real estate and exempt market securities.

Sean McMahon is a Senior Account Manager at OurCrowd who works mainly with investors in North America.

Own current profile describes helping IBM Ventures portfolio companies work with IBM across business and commercial partnerships.

Sidhesh Kanade is an Account Manager at OurCrowd, with over six years of experience across investment banking, private credit, and alternative investments, specializing in financial analysis, deal execution, and portfolio management.

Steve is a co-founder and serves as Co-Chairman of Pathstone, which serves families, family offices, and endowments and foundations.

Zohaib Ahmad is a Senior Account Manager at OurCrowd who works with investors in Canada and the Northeast region of the United States.

Shionogi & Co., Ltd. is the Osaka-headquartered Japanese pharmaceutical parent company, established March17,1878 and incorporated June5,1919. It researches, develops, manufactures and distributes medicines, diagnostic reagents and medical devices, with programs in infectious diseases, neuroscience, pain and rare diseases. Its digital-health work includes Akili-derived ADHD therapeutics and AI-supported drug discovery. Shionogi also makes strategic corporate investments: issuer filings confirm an actual USD5M cash corporate bond to Akili in March2019, distinct from licensing payments, royalties, contingent milestones and later equity transactions. The company established an internal Corporate Venture Capital group in April2025, investing across healthcare technologies and value-chain innovations in Japan, the US, Europe and Asia. Its disclosed FY2025 USD7M setup/investment budget and approximately USD14M planned annual budget are corporate allocations, not closed outside-LP venture funds. The current primary company directory publishes 27 unique directors and corporate officers; its CVC page additionally names six investment-team members, all included here. Isao Teshirogi is representative director, president and CEO; independent outside director Keiichi Ando chairs the board. This profile represents Shionogi & Co., Ltd., not its separate Shionogi Inc. US company, European companies, Shionogi Healthcare retail subsidiary or an independently assumed fund manager. Paid-in capital, operating revenue and licensing budgets are not new funding rounds. Shionogi is listed on the Tokyo Stock Exchange Prime Market under securities code4507. Its current pipeline includes investigational conversational AI cognitive-function testing SDS-881 with FRONTEO and neuroscience drug candidates; a research or licensing collaboration is not automatically an equity investment. In March2026 it obtained two distinct unsecured corporate bridge loans from Sumitomo Mitsui Banking Corporation: JPY360B for acquiring edaravone/RADICAVA rights and JPY300B for additional ViiV equity. These are company debt financings, not venture funds; the JPY660B total is not a third raise.

Akira Kato is publicly listed in Shionogi’s June2026 parent-company leadership directory as Senior Executive Officer, Senior Vice President, Supply Supervisory Unit. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Emi Kato is a member of Shionogi’s CVC Group and holds an MBA. She joined the company in2012 and previously worked in pharmaceutical sales and pain-management marketing, including regional sales strategy in Japan.

Fumi Takatsuki is an independent outside director and audit and supervisory committee member at Shionogi. She is a partner at Oh-Ebashi LPC & Partners, with international corporate-law and Chinese life-sciences/healthcare experience. She first became a Shionogi outside director in2020 and a committee-member director in2025.

Haruyo Konishi is a member of Shionogi’s CVC Group focused on evaluating technologies and science-based investment opportunities. She joined the company in2012 and previously conducted drug-discovery pharmacology research, including fibrosis and hearing-loss programs.

Hiroshi Ozaki is an independent outside director of Shionogi. He formerly served as president and chairman of Osaka Gas and brings energy-industry and corporate-management experience to the board. He joined Shionogi’s board in June2019.

Isao Teshirogi is Shionogi’s representative director, president and CEO. He joined the company in 1982 and became president in 2008, leading its global research, development and corporate transformation strategy. His doctorate is publicly listed by the company.

John Keller is a Shionogi director and senior executive officer overseeing the R&D Supervisory Unit. He joined Shionogi Inc. in 2010 and formerly led that US subsidiary as president and CEO, before holding global-business and corporate-strategy leadership roles. He became a parent-company director in June2025. This pharmaceutical executive is distinct from Redlist co-founder John Keller.

Kazuhiro Hatanaka is publicly listed in Shionogi’s June2026 parent-company leadership directory as Senior Executive Officer, Senior Vice President, Corporate Supervisory Unit. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Kazuyuki Saito is a member of Shionogi’s CVC Group. He joined the company in2017 and brings global supply-chain strategy, commercial supply-chain development and startup-partnership experience.

Keiichi Ando is an independent outside director and chairperson of Shionogi’s board. His background includes executive leadership at Sumitomo Mitsui Banking Corporation and New Kansai International Airport Company. Shionogi first appointed him an outside director in June2016.

Keiichi Yoshii is an independent outside director of Shionogi, appointed in June2026. His corporate-management background includes leading Daiwa House Industry as president and later chairman and CEO, with overseas-business responsibility.

Keisuke Kusumoto leads Shionogi’s CVC Group as general manager within corporate planning and strategy. He joined Shionogi in2008 and previously worked in drug-discovery research and new-product planning, including anti-obesity drug development and asset evaluation. He holds an MBA.

Kenji Matsuo is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Vice President, Internal Control Department. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Kensuke Matsumura is a member of Shionogi’s CVC Group. He joined the company in2020, with neuroscience, AI-assisted drug-discovery and global clinical-development experience. His doctoral research at Osaka University addressed neurodevelopmental disorders, and his Shionogi research has included dementia and rare diseases.

Koji Hanasaki is a Shionogi director and audit and supervisory committee member. His prior company roles include finance and accounting, corporate strategy, global business and supply leadership. He became a committee-member director in June2025.

Kyoko Hirose is an independent outside director of Shionogi, appointed in June2025. She is president of Hirose Manufacturing, a global industrial-sewing-machine component business, and vice-chair of the Osaka Chamber of Commerce and Industry. Her board expertise includes organizational culture, diversity, globalization and risk management.

Li Jiang is a member of Shionogi’s CVC Group in corporate planning and strategy. He joined the company in2013 and previously worked in pharmaceutical sales, Asian business development and joint-venture management. He is distinct from Makers Fund advisor Jiang Li and Sunflower founder Liu Jiang.

Masako Kudou is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Corporate Strategy Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Masashi Deguchi is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Sustainability Management Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Noriyuki Kishida is a Shionogi director and member of its audit and supervisory committee. He joined the company in1984 and held communications, human-resources, administration and corporate-supervisory leadership roles before becoming an auditor and then a committee-member director.

Satoru Yoshimoto is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Integrated Disease Care Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Shuichi Okuhara is an independent outside director and audit and supervisory committee member at Shionogi. His background includes venture-capital management and evaluating innovation partnerships and corporate investment.

Takaoki Fujiwara is an independent outside director of Shionogi. He formerly led Hanshin Electric Railway as president and chairman and held leadership roles at Hankyu Hanshin Holdings and Hanshin Hotel Systems. He became a Shionogi outside auditor in2018 and an outside director in2023.

Takeki Uehara is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Drug Development and Regulatory Science Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Takeshi Shiota is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Corporate Quality Assurance and Ethics & Compliance Management Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Tatsumori Yoshida is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Pharmaceutical Technology Research Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Tetsuya Numa is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Vaccine Business Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Toshinobu Iwasaki is publicly listed in Shionogi’s June2026 parent-company leadership directory as Senior Executive Officer, Senior Vice President, Healthcare Business Supervisory Unit. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Toshiyuki Asaki is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Drug Discovery Research Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Yasuyoshi Iso is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, President, Shionogi Pharma Co., Ltd.. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Yoriko Goto is an independent outside director and chairperson of Shionogi’s audit and supervisory committee. Her background includes professional-services and financial-sector leadership at Deloitte.

Yoshinori Yurugi is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, Pharmaceutical Commercial Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Yousuke Miharu is publicly listed in Shionogi’s June2026 parent-company leadership directory as Corporate Officer, Senior Vice President, DX Promotion Division. Further personal biography and an authentic individual portrait are not published in that roster; no appointment date or subsidiary legal ownership is inferred.

Brant Shrimplin’s public regulatory disclosure identifies investor-relations work for venture fund Community Access Management III starting December17,2021. He separately co-founded 626 Financial in 2009 and is a Managing Director there, advising entrepreneurial families on wealth, private markets and real estate. He began his financial-services career on the New York Stock Exchange in 1999 and holds a business-administration degree from Western Washington University.

Tom Anderton is a published member of the Community Access Fund investment team and is identified as Thomas William Anderton, a member of Community Access Management III LLC, in its March2024 adviser filing. He is also Managing Director at the separate wealth-advisory firm 626 Financial. He studied finance at the University of Florida and earned an MBA at the University of Chicago; his investment career included Oppenheimer before returning to Kalamazoo. Community Access Fund does not publish a more specific operating title for him.

Sean Sternbach is Managing Partner of Community Access Fund, a role disclosed since September 2019 in his public regulatory record. He supports founders through Venture Out, which helps people from technology companies validate startup ideas. His earlier career includes product management at Amazon, co-founding Gingr and a Techstars contractor role. His Cloud Capital investment-adviser work is a separate disclosed activity.

Community Access Fund is an early-stage venture-capital firm based in Seattle, founded in 2019. It supports startup founders with capital and a network of founders, mentors and advisers, including the Venture Out community for founders from technology companies. Its published team includes Managing Partner Sean Sternbach, Tom Anderton and Patrick Thompson; a public regulatory disclosure also identifies Brant Shrimplin as investor-relations support for Community Access Management III. Community Access Management III LLC is the legally identified management entity in the March 2024 state exempt-reporting-adviser filing, CRD327370, which explicitly publishes the firm’s website. Community Access Fund is the investing brand; its individual funds and special-purpose vehicles remain distinct legal entities. The public portfolio spans AI and developer infrastructure, aerospace, robotics and life-science technology, including Genemod, Luxonis, Agile Space Industries, GrowthBook and Kamiwaza. Five exact private vehicles are reported in the manager’s filing, including Community Access Fund III LLC and four company-specific vehicles. Their reported gross asset values do not establish completed fundraising or paid company checks. The exact current fund commitments and closing dates are not publicly verified.

UK EIS investment manager backing early-stage and growing technology businesses with established technology, substantial addressable markets and opportunities to scale. Its focus includes applied AI, robotics, industrial and clean technologies, cybersecurity, software and quantum computing. The manager combines portfolio selection, investment governance and company support with the regional resources of parent Maven Capital Partners. The same legal entity previously operated as Newable Ventures and LBA Ventures; Newable Ventures participated in SERG Technologies’ July 2022 seed financing. Following acquisition and renaming in 2024, the business operates as Maven Cognition and offers the Maven Cognition EIS Fund.

Chloe Woodacre is published by Parkwalk as Head of Investor Relations.

Danielle Acuy is published by Parkwalk as Senior Business & Data Analyst.

Maven operations executive with experience in acquisitions, due diligence, legal and financial structuring, asset management and investment operations. Companies House identifies him as a current director of Maven Cognition.

George Van Horn is published in Parkwalk’s institutional team as Vice President, IP Capital. This IP Capital affiliation is distinguished from the core Parkwalk investment team.

Georgia Docker is published by Parkwalk as Senior Investor Relations Associate.

Gordon Lawson is published by Parkwalk as Non-Executive Chairman.

Helen Redmond is published by Parkwalk as Chief Risk Officer.

Lucy Allen is published by Parkwalk as Marketing Manager.

Moray Wright is published by Parkwalk as Chief Executive Officer.

Olivia Smith is published by Parkwalk as Investor Relations Manager.

Richard Male leads Maven Cognition’s strategy, fundraising, investor support and investment governance. His background combines venture investing, research commercialisation and public–private partnerships, with particular experience in applied AI, robotics, industrial technology and software.

Samiksha Rai is published by Parkwalk as Investor Relations Assistant.

Wisdom Yemi is published by Parkwalk as Investment Associate.

Professor David Onions is Norcliffe Capital’s Chief Scientific Officer and science specialist. The manager biography identifies a PhD in virology and previous roles as Professor of Veterinary Pathology at the University of Glasgow and director of the Leukaemia Research Fund’s Human Virus Centre. It describes scientific and commercial leadership, due diligence and mentorship of life-sciences founders. His scientific role is distinct from Patricia Reynolds’s CEO/director role and does not itself establish a personal company investment.

Patricia Reynolds is the founder and CEO of Norcliffe Capital. Its current biography describes over30years in finance, including15years at RBS, and work since2013 in pre-investment due diligence, EIS/SEIS equity fundraising and post-investment business management across life sciences, healthcare, technology and IoT. Companies House identifies Patricia Elaine Reynolds as the active director of Norcliffe Capital Limited, appointed1February2018. Exact career-date labels are company biography claims; no personal portfolio check is inferred.

Norcliffe Capital is a UK life-sciences investment and fundraising business focused on tax-efficient direct investments in medical technology and biotechnology companies. It connects high-net-worth investors, advisers and other capital providers with EIS/SEIS-eligible private-company opportunities and supports investees through due diligence, equity fundraising and commercial development. Its published portfolio includes neurovascular devices, brain-cancer diagnostics, biomaterials and molecular-analysis technology. The exact legal company is Norcliffe Capital Limited, UK number11181154, incorporated1February2018; its current website dates the operating brand to2020. FCA reference826977 is an appointed representative of Sturgeon Ventures LLP, reference452811, rather than a separately authorised regulated firm. The public model is direct company investment by clients, not a verified pooled55Mventurefund: the website’s55Mfundsraised is an aggregate firm claim with no exact fund/closingdate. Norcliffe Nominees is a distinct administrative nominee for underlying investors and is not automatically the manager’s own cash buyer.

Blue Ocean Capital Group is a life-science venture capital firm investing in biotechnology, medical devices and health technology across Greater China, the United States and Northern Europe. It backs research commercialization and helps portfolio companies develop products, operating teams and international partnerships. Its investment themes include RNA drugs, gene and cell therapies, AI drug discovery, medical imaging and digital health; its specialist seed strategy also targets brain-computer interfaces and neuroscience.

Sanbo Brain Hospital Group operates specialist neuroscience hospitals and general hospitals in China. It provides clinical care for neurological and neurosurgical conditions, combines hospital investment and management with medical education and research, and supports the development and clinical application of neuroscience technologies. Its listed legal issuer is Sanbo Brain Hospital Management Group Co., Ltd. (Shenzhen: 301293).